Document:

<PAGE>
                                                                   Exhibit 10.22

                           LOAN AND SECURITY AGREEMENT

     This LOAN AND SECURITY AGREEMENT (this "Agreement") dated as of June 15,
2000, between SILICON VALLEY BANK, a California-chartered bank, with its
principal place of business at 3003 Tasman Drive, Santa Clara, California 95054
and with a loan production office located at Wellesley Office Park, 40 William
Street, Suite 350, Wellesley, Massachusetts 02481, doing business under the name
"Silicon Valley East" ("Bank") and VIACELL, INC., a Delaware corporation, with
offices at One Innovation Drive, Worcester, Massachusetts 01608 ("Borrower"),
provides the terms on which Bank shall lend to Borrower and Borrower shall repay
Bank. The parties agree as follows:

     1. ACCOUNTING AND OTHER TERMS

     Accounting terms not defined in this Agreement shall be construed following
GAAP. Calculations and determinations must be made following GAAP. The term
"financial statements" includes the notes and schedules. The terms "including"
and "includes" always mean "including (or includes) without limitation" in this
or any Loan Document. Capitalized terms in this Agreement shall have the
meanings set forth in Section 13. This Agreement shall be construed to impart
upon Bank a duty to act reasonably at all times.

     2. LOAN AND TERMS OF PAYMENT

     2.1 CREDIT EXTENSIONS. Borrower shall pay Bank the unpaid principal amount
of all Credit Extensions and interest on the unpaid principal amount of the
Credit Extensions as and when due in accordance with this Agreement.

     2.1.1 EQUIPMENT ADVANCES.

           (a) Subject to the terms and conditions of this Agreement, Bank
agrees to lend to Borrower, from time to time prior to the Commitment
Termination Date, equipment advances (each an "Equipment Advance" and
collectively the "Equipment Advances") in an aggregate amount not to exceed the
Committed Equipment Line. Notwithstanding the foregoing, no Equipment Advances
shall be made until Viacord, Inc. executes a Guaranty in favor of the Bank and
provides authority documents to the Bank in connection therewith, each in form
and substance acceptable to the Bank. When repaid, the Equipment Advances may
not be re-borrowed. The proceeds of the Equipment Advances shall be used solely
to reimburse Borrower for the purchase of Eligible Equipment purchased within
sixty (60) days (determined based upon the applicable invoice date of such
Eligible Equipment) of the Equipment Advance. Notwithstanding the foregoing, an
Equipment Advance made on the Closing Date may be used to reimburse Borrower for
the purchase of Eligible Equipment purchased on or after July 1, 1999. Bank's
obligation to lend hereunder shall terminate on the earlier of (i) the
occurrence and continuance of an Event of Default, or (ii) the Commitment
Termination Date. For purposes of this Section, the minimum amount of each
Equipment Advance is Fifty Thousand Dollars ($50,000.00). The Borrower may
request no more than six (6) Equipment Advances for the refinance of Equipment.

           (b) To obtain an Equipment Advance, Borrower shall deliver to Bank a
completed supplement in substantially the form attached as EXHIBIT B ("Loan
Supplement"), together with a UCC Financing Statement covering the Financed
Equipment described on Annex A to the applicable Loan Supplement and such
additional information as Bank may reasonably request at least five (5) Business
Days before the proposed funding date (the "Funding Date"). On each Funding
Date, Bank shall specify in the Loan Supplement for each Equipment Advance, the
Basic Rate, and the Payment Dates. If Borrower satisfies the conditions of each
Equipment Advance, Bank shall disburse such Equipment Advance by internal
transfer to Borrower's deposit account with Bank. Each Equipment Advance may not
exceed 100% of the Original Stated Cost of the Financed Equipment.

           (c) Bank's obligation to lend the undisbursed portion of the
Committed Equipment Line shall terminate if there has been a material adverse
change in the general affairs, management, results of operation, condition
(financial or otherwise) or the prospects of Borrower, whether or not arising
from transactions in the ordinary course of business,

<PAGE>

or there has been any material adverse deviation by Borrower from the most
recent business plan of Borrower presented to and accepted by Bank prior to the
execution of this Agreement.

     2.2 INTEREST RATE; PAYMENTS.

           (a) PRINCIPAL AND INTEREST PAYMENTS ON PAYMENT DATES. Borrower shall
repay each Equipment Advance pursuant to the terms set forth in the
corresponding Loan Supplement. For each Equipment Advance, Borrower shall make
equal monthly payments of principal and interest, in advance, calculated by the
Bank based upon: (1) the amount of the Equipment Advance, (2) the Basic Rate,
and (3)an amortization schedule equal to the Repayment Period (individually, the
"Scheduled Payment", and collectively, "Scheduled Payments"), on the first
Business Day of the month following the month in which the Funding Date occurs
(or commencing on the Funding Date if the Funding Date is the first Business Day
of the month) with respect to such Equipment Advance and continuing thereafter
during the Repayment Period on the first Business Day of each successive
calendar month (each a "Payment Date"). All unpaid principal and accrued
interest, is due and payable in full on the last Payment Date with respect to
such Equipment Advance. Payments received after 12:00 noon Eastern time are
considered received at the opening of business on the next Business Day. An
Equipment Advance may only be prepaid in accordance with Sections 2.2(d) and
2.2(f).

           (b) INTEREST RATE. Borrower shall pay interest on the unpaid
principal amount of each Equipment Advance until the Equipment Advance has been
paid in full, at the per annum rate of interest equal to the Basic Rate
determined by Bank as of the Funding Date for each Equipment Advance in
accordance with the definition of the Basic Rate. Any amounts outstanding during
the continuance of an Event of Default shall bear interest at a per annum rate
equal to the Basic Rate plus five percent (5%)(the "Default Rate"). If any
change in the law increases Bank's expenses or decreases its return from the
Equipment Advances, Borrower shall pay Bank upon request the amount of such
increase or decrease.

           (c) PREPAID INTEREST. In the event that the Funding Date is not the
first Business Day of a month, on the Funding Date for each Equipment Advance,
Borrower shall pay to Bank, on behalf of Bank, an amount ("Prepaid Interest")
equal to the interest which shall accrue at the Basic Rate respect to such
Equipment Advance through the last day of the subject month.

           (d) PREPAYMENT UPON AN EVENT OF LOSS. If any Financed Equipment is
subject to an Event of Loss and Borrower is required to or elects to prepay the
Equipment Advance with respect to such Financed Equipment pursuant to Section
6.8, then such Equipment Advance shall be prepaid to the extent and in the
manner provided in such section.

           (e) MANDATORY PREPAYMENT UPON AN ACCELERATION. If the Equipment
Advances are accelerated following the occurrence of an Event of Default or
otherwise, Borrower shall immediately pay to Bank an amount equal to the sum of:
(i) all outstanding principal plus accrued interest, plus (ii) all other sums,
if any, that shall have become due and payable, including interest at the
Default Rate with respect to any past due amounts.

           (f) PERMITTED PREPAYMENT OF LOANS. With Bank's prior written consent,
which shall not be unreasonably withheld, Borrower shall have the option to
prepay all, but not less than all, of the Equipment Advances advanced by Bank
under this Agreement, PROVIDED Borrower(i) provides written notice to Bank of
its election to prepay the Equipment Advances at least ten (10) days prior to
such prepayment, and (ii) pays, on the date of such prepayment (A) all
outstanding principal plus accrued interest, plus (B) all other sums, if any,
that shall have become due and payable, including interest at the Default Rate
with respect to any past due amounts.

                                       2

<PAGE>

     2.3 FEES. Borrower shall pay to Bank:

           (a) FACILITY FEE. A fully earned, non-refundable facility fee of Two
Thousand Five Hundred ($2,500.00) Dollars due on the Closing Date; and

           (b) BANK EXPENSES. All Bank Expenses (including reasonable attorneys'
fees and expenses incurred through and after the Closing Date) when due.

     3. CONDITIONS OF LOANS

     3.1 CONDITIONS PRECEDENT TO INITIAL CREDIT EXTENSION. The obligation
of Bank to make the initial Credit Extension is subject to the condition
precedent that Bank shall have received, in form and substance satisfactory to
Bank, the following:

           (a) this Agreement;

           (b) a certificate of the Secretary of Borrower with respect to
     articles, bylaws, incumbency and resolutions authorizing the execution and
     delivery of this Agreement;

           (c) negative pledge agreement covering intellectual property;

           (d) guaranty by the Guarantor;

           (e) an opinion of Borrower's counsel;

           (f) financing statements (Forms UCC-1);

           (g) insurance certificate;

           (h) payment of the fees and Bank Expenses then due specified in
     Section 2.3 hereof;

           (i) Certificate of Foreign Qualification (if applicable);

           (j) Certificate of Good Standing/Legal Existence; and

           (k) such other documents, and completion of such other matters, as
     Bank may reasonably deem necessary or appropriate.

     3.2 CONDITIONS PRECEDENT TO ALL CREDIT EXTENSIONS. Bank's obligations
to make each Credit Extension, including the initial Credit Extension, is
subject to the following:

           (a) timely receipt of a completed Loan Supplement and UCC financing
statement covering the Financed Equipment described on Annex A to the Loan
Supplement; and

           (b) the representations and warranties in Article 5 must be
materially true on the date of the Loan Supplement and on the effective date of
each Credit Extension and no Event of Default shall have occurred and be
continuing as of such effective date, or result from the Credit Extension. Each
Credit Extension is Borrower's representation and warranty on that date that the
representations and warranties in Article 5 remain true.

           (c) the Bank shall have the opportunity to confirm that upon filing
the UCC-l financing statement covering the Equipment described on the Loan
Supplement, that the Bank shall have a first perfected security interest in such
Equipment.

                                       3

<PAGE>

     4. CREATION OF SECURITY INTEREST

     4.1 GRANT OF SECURITY INTEREST. Borrower grants Bank a continuing
security interest in all presently existing and later acquired Collateral to
secure all Obligations and performance of each of Borrower's duties under the
Loan Documents. Any security interest shall be a first priority security
interest in the Collateral. If the Agreement is terminated, Bank's lien and
security interest in the Collateral shall continue until Borrower fully
satisfies its Obligations.

     5. REPRESENTATIONS AND WARRANTIES

     Borrower represents and warrants as follows:

     5.1 DUE ORGANIZATION AND AUTHORIZATION. Borrower and each Subsidiary is
duly existing and in good standing in its state of formation and qualified and
licensed to do business in, and in good standing in, any state in which the
conduct of its business or its ownership of property requires that it be
qualified.

     The execution, delivery and performance of the Loan Documents have been
duly authorized, and do not conflict with Borrower's organizational documents,
nor constitute an event of default under any material agreement by which
Borrower is bound. Borrower is not in default under any agreement to which or by
which it is bound in which the default could cause a Material Adverse Change.

     5.2 COLLATERAL. Borrower has good title to the Collateral, free of Liens.

     5.3 LITIGATION. Except as shown in the Schedule, there are no actions or
proceedings pending or, to Borrower's knowledge, threatened by or against
Borrower or any Subsidiary in which an adverse decision could cause a Material
Adverse Change.

     5.4 NO MATERIAL ADVERSE CHANGE IN FINANCIAL STATEMENTS. All consolidated
financial statements for Borrower and any Subsidiary delivered to Bank fairly
present in all material respects Borrower's consolidated financial condition and
Borrower's consolidated results of operations. There has not been any material
deterioration in Borrower's consolidated financial condition since the date of
the most recent financial statements submitted to Bank.

     5.5 SOLVENCY. Borrower is able to pay its debts (including trade debts) as
they mature.

     5.6 REGULATORY COMPLIANCE. Borrower is not an "investment company" or a
company "controlled" by an "investment company" under the Investment Company
Act. Borrower is not engaged as one of its important activities in extending
credit for margin stock (under Regulations T and U of the Federal Reserve
Board of Governors). Borrower has complied with the Federal Fair Labor
Standards Act. Borrower has not violated any laws, ordinances or rules, the
violation of which could reasonably be expected to cause a Material Adverse
Change. None of Borrower's or any Subsidiary's properties or assets has been
used by Borrower or any Subsidiary or, to the best of Borrower's knowledge,
by previous Persons, in disposing, producing, storing, treating, or
transporting any hazardous substance other than legally. Borrower and each
Subsidiary has timely filed all required tax returns and paid, or made
adequate provision to pay, all material taxes. Borrower and each Subsidiary
has obtained all consents, approvals and authorizations of, made all
declarations or filings with, and, given all notices to, all government
authorities that are necessary to continue its business as currently
conducted.

     5.7 SUBSIDIARIES. Borrower does not own any stock, partnership interest or
other equity securities, except for its ownership interest of one hundred
percent (100%) of the outstanding capital stock of Viacord, Inc., a Delaware
corporation.

     5.8 FULL DISCLOSURE. No representation, warranty or other statement of
Borrower in any certificate or written statement given to Bank contains any
untrue statement of a material fact or omits to state a material fact necessary
to make the statements contained in the certificates or statements not
misleading.

                                       4

<PAGE>

     6. AFFIRMATIVE COVENANTS

     Borrower shall do all of the following:

     6.1 GOVERNMENT COMPLIANCE. Borrower shall maintain its and all
Subsidiaries' corporate existence and good standing in its jurisdiction of
incorporation and maintain qualification in each jurisdiction in which the
failure to so qualify could have a material adverse effect on Borrower's
business or operations. Borrower shall comply, and have each Subsidiary comply,
with all laws, ordinances and regulations to which it is subject, noncompliance
with which could have a material adverse effect on Borrower's business or
operations or cause a Material Adverse Change.

     6.2 FINANCIAL STATEMENTS, REPORTS, CERTIFICATES.

           (a) Borrower shall deliver to Bank: (i) as soon as available, but no
later than thirty (30) days after the last day of each month, a company prepared
consolidated balance sheet and income statement covering Borrower's consolidated
operations during the period, in a form acceptable to Bank and certified by a
Responsible Officer; (ii) as soon as available, but no later than one hundred
twenty (120) days after the end of Borrower's fiscal year, audited, consolidated
financial statements prepared under GAAP, consistently applied, together with an
unqualified opinion on the financial statements from an independent certified
public accounting firm acceptable to Bank; (iii)within five (5) days of filing,
copies of all statements, reports and notices made available to Borrower's
security holders or to any holders of Subordinated Debt and all reports on Form
10-K, l0-Q and 8-K filed with the Securities and Exchange Commission; (iv) a
prompt report of any legal actions pending or threatened against Borrower or any
Subsidiary that could result in damages or costs to Borrower or any Subsidiary
of One Hundred Thousand Dollars ($100,000.00) or more; and (v) budgets, sales
projections, operating plans or other financial information Bank requests.

           (b) Within thirty (30) days after the last day of each month,
Borrower shall deliver to Bank with the monthly financial statements a
Compliance Certificate signed by a Responsible Officer in the form of Exhibit C.

     6.3 TAXES. Borrower shall make, and cause each Subsidiary to make, timely
payment of all material federal, state, and local taxes or assessments owing by
Borrower and shall deliver to Bank, on demand, appropriate certificates
attesting to such payments.

     6.4 INSURANCE. Borrower shall keep its business and the Collateral insured
for risks and in amounts, as Bank requests. Insurance policies shall be in a
form, with companies, and in amounts that are reasonably satisfactory to Bank.
All property policies shall have a lender's loss payable endorsement showing
Bank as an additional loss payee and all liability policies shall show the Bank
as an additional insured and all policies shall provide that the insurer must
give Bank at least twenty (20) days notice before canceling its policy. At
Bank's request, Borrower shall deliver certified copies of policies and evidence
of all premium payments. Proceeds payable under any policy shall, at Bank's
option, be payable to Bank on account of the Obligations. Notwithstanding the
foregoing, so long as no Event of Default has occurred and is continuing,
Borrower shall have the option of applying the proceeds of any casualty policy
up to Fifty Thousand Dollars ($50,000.00) toward the replacement or repair of
destroyed or damaged property; provided that (i) any such replaced or repaired
property (a) shall be of equal or like value as the replaced or repaired
Collateral and (b) shall be deemed Collateral in which Bank has been granted a
first priority security interest and (ii) after the occurrence and during the
continuation of an Event of Default all proceeds payable under such casualty
policy shall, at the option of the Bank, be payable to Bank on account of the
Obligations. To the extent that Bank receives proceeds of an insurance policy
relating to losses unrelated to the Collateral, Bank shall pay over such
proceeds to Borrower.

     6.5 PRIMARY ACCOUNTS. Borrower shall maintain its primary depository and
operating accounts with Bank.

                                       5

<PAGE>

     6.6 FINANCIAL COVENANTS.

     Borrower shall maintain as of the last day of each month, unless otherwise
noted:

           (a) QUICK RATIO. A ratio of Quick Assets to Current Liabilities of at
least 1.5 to 1.0.

           (b) CASH BURN. Four (4) months of Cash Burn.

     6.7 FURTHER ASSURANCES. Borrower shall execute any further instruments and
take further action as Bank requests to perfect or continue Bank's security
interest in the Collateral or to effect the purposes of this Agreement.

     6.8 LOSS; DESTRUCTION; OR DAMAGE. Borrower shall bear the risk of the
Financed Equipment being lost, stolen, destroyed, or damaged. If during the term
of this Agreement any item of Financed Equipment becomes obsolete or is lost,
stolen, destroyed, damaged beyond repair, rendered permanently unfit for use, or
seized by a governmental authority for any reason for a period equal to at least
the remainder of the term of this Agreement (an "Event of Loss"), then in each
case, Borrower:

           (a) prior to the occurrence of an Event of Default, at Borrower's
option, shall (i) pay to Bank on account of the Obligations all accrued interest
to the date of the prepayment, plus all outstanding principal; or (ii) repair or
replace any Financed Equipment subject to an Event of Loss provided the repaired
or replaced Financed Equipment is of equal or like value to the Financed
Equipment subject to an Event of Loss and provided further that Bank has a first
priority perfected security interest in such repaired or replaced Financed
Equipment.

           (b) during the continuance of an Event of Default, on or before the
next Payment Date following such Event of Loss, for each such item of Financed
Equipment subject to such Event of Loss, Borrower shall, at Bank's option, pay
to Bank an amount equal to the sum of: (i) all outstanding principal plus
accrued interest, plus (ii) all other sums, if any, that shall have become due
and payable, including interest at the Default Rate with respect to any past due
amounts.

     7. NEGATIVE COVENANTS

     Borrower shall not do any of the following without the Bank's written
consent:

     7.1 CHANGES IN BUSINESS OR BUSINESS LOCATIONS, COMPLIANCE. Change its name
or the chief executive office or principal place of business, move or dispose of
any interest in the Collateral, permit any lien or security interest to attach
to the Collateral, or enter into any transaction outside the ordinary course of
Borrower's business.

     Become an "investment company" or a company controlled by an "investment
company", under the Investment Company Act of 1940 or undertake as one of its
important activities extending credit to purchase or carry margin stock, or use
the proceeds of any Equipment Advance for that purpose; fail to meet the minimum
funding requirements of ERISA, permit a Reportable Event or Prohibited
Transaction, as defined in ERISA, to occur; fail to comply with the Federal Fair
Labor Standards Act or violate any other law or regulation, if the violation
could have a material adverse effect on Borrower's business or operations or
cause a Material Adverse Change, or permit any of its Subsidiaries to do so.

     7.2 ENCUMBRANCES. Permit any Collateral not to be subject to Bank's first
priority security interest in the Collateral granted herein.

     8. EVENTS OF DEFAULT

     Any one of the following is an Event of Default:

                                       6

<PAGE>

     8.1 PAYMENT DEFAULT. Borrower fails to pay any of the Obligations within
three (3) days after their due date. During the additional period the failure to
cure the default is not an Event of Default (but no Credit Extensions shall be
made during the cure period);

     8.2 COVENANT DEFAULT. Borrower does not perform any obligation in Section 6
or violates any covenant in Section 7 or does not perform or observe any other
material term, condition or covenant in this Agreement, any Loan Documents, or
in any agreement between Borrower and Bank and as to any default under a term,
condition or covenant that can be cured, has not cured the default within ten
(10) days after it occurs, or if the default cannot be cured within ten (10)
days or cannot be cured after Borrower's attempts in the ten (10) day period,
and the default may be cured within a reasonable time, then Borrower shall have
additional time, (of not more than thirty (30) days) to attempt to cure the
default. During the additional period the failure to cure the default is not an
Event of Default (but no Credit Extensions shall be made during the cure
period);

     8.3 MATERIAL ADVERSE CHANGE. A Material Adverse Change occurs;

     8.4 ATTACHMENT. (i) Any material portion of Borrower's assets is attached,
seized, levied on, or comes into possession of a trustee or receiver and the
attachment, seizure or levy is not removed in thirty (30) days; (ii) Borrower is
enjoined, restrained, or prevented by court order from conducting a material
part of its business; (iii) a judgment or other claim becomes a Lien on a
material portion of Borrower's assets; or (iv) a notice of lien, levy, or
assessment is filed against any of Borrower's assets by any government agency
and not paid within ten (10) days after Borrower receives notice. These are not
Events of Default if stayed or if a bond is posted pending contest by Borrower
(but no Credit Extensions shall be made during the cure period);

     8.5 INSOLVENCY. (i) Borrower becomes insolvent; (ii) Borrower begins an
Insolvency Proceeding; or (iii) an Insolvency Proceeding is begun against
Borrower and not dismissed or stayed within forty-five (45) days (but no Credit
Extensions shall be made before any Insolvency Proceeding is dismissed);

     8.6 OTHER AGREEMENTS. If there is a default in any agreement to which
Borrower is a party with a third party or parties resulting in a right by such
third party or parties, whether or not exercised, to accelerate the maturity of
any Indebtedness in an amount in excess of One Hundred Thousand Dollars
($100,000.00) or that could result in a Material Adverse Change;

     8.7 JUDGMENTS. If a judgment or judgments for the payment of money in an
amount, individually or in the aggregate, of at least Two Hundred Thousand
Dollars ($200,000.00) shall be rendered against Borrower and shall remain
unsatisfied and unstayed for a period of thirty (30) days (provided that no
Credit Extensions will be made prior to the satisfaction or stay of such
judgment);

     8.8 MISREPRESENTATIONS. If Borrower or any Person acting for Borrower makes
any material misrepresentation or material misstatement now or later in any
warranty or representation in this Agreement or in any communication delivered
to Bank or to induce Bank to enter this Agreement or any Loan Document.

     8.9 GUARANTY. Any guaranty of any Obligations ceases for any reason to be
in full force or any Guarantor does not perform any obligation under any
guaranty of the Obligations, or any material misrepresentation or material
misstatement exists now or later in any warranty or representation in any
guaranty of the Obligations or in any certificate delivered to Bank in
connection with the guaranty, or any circumstance described in Sections 8.4, 8.5
or 8.7 occurs to any Guarantor.

     9. BANK'S RIGHTS AND REMEDIES

     9.1 RIGHTS AND REMEDIES. When an Event of Default occurs and continues Bank
may, without notice or demand, do any or all of the following:

                                       7

<PAGE>

          (a) Declare all Obligations immediately due and payable (but if an
     Event of Default described in Section 8.5 occurs all Obligations are
     immediately due and payable without any action by Bank);

          (b) Stop advancing money or extending credit for Borrower's benefit
     under this Agreement or under any other agreement between Borrower and
     Bank;

          (c) Make any payments and do any acts it considers necessary or
     reasonable to protect its security interest in the Collateral. Borrower
     shall assemble the Collateral if Bank requests and make it available as
     Bank designates. Bank may enter premises where the Collateral is located,
     take and maintain possession of any part of the Collateral, and pay,
     purchase, contest or compromise any Lien which appears to be prior or
     superior to its security interest and pay all expenses incurred. Borrower
     grants Bank a license to enter and occupy any of its premises, without
     charge, to exercise any of Bank's rights or remedies;

          (d) Ship, reclaim, recover, store, finish, maintain, repair, prepare
     for sale, advertise for sale, and sell the Collateral; and

          (e) Dispose of the Collateral according to the Code.

     9.2 POWER OF ATTORNEY. Borrower hereby irrevocably appoints Bank as its
lawful attorney-in-fact, to be effective upon the occurrence and during the
continuance of an Event of Default, to: (i) endorse Borrower's name on any
checks or other forms of payment or security; (ii) make, settle, and adjust all
claims under Borrower's insurance policies; and (iii) transfer the Collateral
into the name of Bank or a third party as the Code permits. Borrower hereby
appoints Bank its power of attorney to sign Borrower's name on any documents
necessary to perfect or continue the perfection of any security interest
regardless of whether an Event of Default has occurred until all Obligations
have been satisfied in full and Bank is under no further obligation to make
Credit Extensions hereunder. Bank's foregoing appointment as Borrower's attorney
in fact, and all of Bank's rights and powers, coupled with an interest, are
irrevocable until all Obligations have been fully repaid and performed and
Bank's obligation to provide Credit Extensions terminates.

     9.3 BANK EXPENSES. If Borrower fails to obtain insurance as required under
Section 6.4 or to pay any amount or furnish any required proof of payment to
third persons and the Bank, Bank may make all or part of the payment or obtain
such insurance policies required in Section 6.4, and take any action under the
policies Bank deems prudent. Any amounts paid by Bank as provided herein are
Bank Expenses and are immediately due and payable, bearing interest at the then
applicable rate and secured by the Collateral. No payments by Bank are deemed an
agreement to make similar payments in the future or Bank's waiver of any Event
of Default.

     9.4 BANK'S LIABILITY FOR COLLATERAL. So long as the Bank complies with
reasonable banking practices regarding the safekeeping of collateral, the Bank
shall not be liable or responsible for: (a) the safekeeping of the Collateral;
(b) any loss or damage to the Collateral; (c) any diminution in the value of the
Collateral; or (d) any act or default of any carrier, warehouseman, bailee, or
other person. Borrower bears all risk of loss, damage or destruction of the
Collateral.

     9.5 REMEDIES CUMULATIVE. Bank's rights and remedies under this Agreement,
the Loan Documents, and all other agreements are cumulative. Bank has all rights
and remedies provided under the Code, by law, or in equity. Bank's exercise of
one right or remedy is not an election, and Bank's waiver of any Event of
Default is not a continuing waiver. Bank's delay is not a waiver, election, or
acquiescence. No waiver is effective unless signed by Bank and then is only
effective for the specific instance and purpose for which it was given.

     9.6 DEMAND WAIVER. Borrower waives demand, notice of default or dishonor,
notice of payment and nonpayment, notice of any default, nonpayment at maturity,
release, compromise, settlement, extension, or renewal of accounts, documents,
instruments, chattel paper, and guaranties held by Bank on which Borrower is
liable.

                                       8

<PAGE>

     10. NOTICES

     All notices or demands by any party to this Agreement or any other related
agreement must be in writing and be personally delivered or sent by an overnight
delivery service, by certified mail, postage prepaid, return receipt requested,
or by telefacsimile at the addresses listed at the beginning of this Agreement.
Either Bank or Borrower may change its notice address by giving the other
written notice.

                  If to Borrower:     ViaCell, Inc.
                                      One Innovation Drive
                                      Worcester, MA 01608
                                      Attn:  Marc Beer, CEO
                                      FAX: (508) 83l-352l/(617) 266-9391

                  If to Bank:         Silicon Valley Bank
                                      40 William Street
                                      Wellesley, Massachusetts 02481
                                      Attn:  Melissa L. Stepanis, Vice President
                                      FAX:  (781)431-9906

                  with a copy to:     Riemer & Braunstein LLP
                                      Three Center Plaza
                                      Boston, Massachusetts 02108
                                      Attn: David A. Ephraim, Esquire
                                      FAX: (617) 880-3456

     11. CHOICE OF LAW, VENUE AND JURY TRIAL WAIVER

     Massachusetts law governs the Loan Documents without regard to principles
of conflicts of law. Borrower and Bank each submit to the exclusive jurisdiction
of the State and Federal courts in Massachusetts; provided, however, that if for
any reason Bank cannot avail itself of such courts in the Commonwealth of
Massachusetts, Borrower accepts jurisdiction of the courts and venue in Santa
Clara County, California.

BORROWER AND BANK EACH WAIVE THEIR RIGHT TO A JURY TRIAL OF ANY CLAIM OR CAUSE
OF ACTION ARISING OUT OF OR BASED UPON THIS AGREEMENT, THE LOAN DOCUMENTS OR ANY
CONTEMPLATED TRANSACTION, INCLUDING CONTRACT, TORT, BREACH OF DUTY AND ALL OTHER
CLAIMS. THIS WAIVER IS A MATERIAL INDUCEMENT FOR BOTH PARTIES TO ENTER INTO THIS
AGREEMENT. EACH PARTY HAS REVIEWED THIS WAIVER WITH ITS COUNSEL.

     12. GENERAL PROVISIONS

     12.1 SUCCESSORS AND ASSIGNS. This Agreement binds and is for the benefit of
the successors and permitted assigns of each party. Borrower may not assign this
Agreement or any rights or Obligations under it without Bank's prior written
consent which may be granted or withheld in Bank's discretion. Bank has the
right, without the consent of or notice to Borrower to sell, transfer,
negotiate, or grant participation in all or any part of, or any interest in,
Bank's obligations, rights and benefits under this Agreement, the Loan Documents
or any related agreement.

     12.2 INDEMNIFICATION. Borrower hereby indemnifies, defends and holds the
Bank and its officers, employees and agents harmless against: (a) all
obligations, demands, claims, and liabilities asserted by any other party in
connection with the transactions contemplated by the Loan Documents; and (b)
all losses or Bank Expenses incurred, or paid by Bank from, following, or
consequential to transactions between Bank and Borrower (including reasonable
attorneys' fees and expenses), except for losses caused by Bank's gross
negligence or willful misconduct.

                                       9

<PAGE>

     12.3 TIME OF ESSENCE. Time is of the essence for the performance of all
Obligations in this Agreement.

     12.4 SEVERABILITY OF PROVISION. Each provision of this Agreement is
severable from every other provision in determining the enforceability of any
provision.

     12.5 AMENDMENTS IN WRITING, INTEGRATION. All amendments to this Agreement
must be in writing signed by both Bank and Borrower. This Agreement and the Loan
Documents represent the entire agreement about this subject matter, and
supersedes prior or contemporaneous negotiations or agreements. All prior or
contemporaneous agreements, understandings, representations, warranties, and
negotiations between the parties about the subject matter of this Agreement and
the Loan Documents merge into this Agreement and the Loan Documents.

     12.6 COUNTERPARTS. This Agreement may be executed in any number of
counterparts and by different parties on separate counterparts, each of which,
when executed and delivered, are an original, and all taken together, are one
Agreement.

     12.7 SURVIVAL. All covenants, representations and warranties made in this
Agreement continue in full force while any Obligations remain outstanding. The
obligations of Borrower in Section 12.2 to indemnify Bank shall survive until
all statutes of limitations for actions that may be brought against Bank have
run.

     12.8 CONFIDENTIALITY. In handling any confidential information, Bank shall
exercise the same degree of care that it exercises for its own proprietary
information, but disclosure of information may be made: (i) to Bank's
subsidiaries or affiliates in connection with their present or prospective
business relations with Borrower; (ii) to prospective transferees or purchasers
of any interest in the Loans; (iii) as required by law, regulation, subpoena, or
other order, (iv) as required in connection with Bank's examination or audit;
and (v) as Bank considers appropriate in exercising remedies under this
Agreement. Confidential information does not include information that either:
(a) is in the public domain or in Bank's possession when disclosed to Bank, or
becomes part of the public domain after disclosure to Bank; or (b) is disclosed
to Bank by a third party, if Bank does not know that the third party is
prohibited from disclosing the information.

     12.9 ATTORNEYS' FEES, COSTS AND EXPENSES. In any action or proceeding
between Borrower and Bank arising out of the Loan Documents, the prevailing
party shall be entitled to recover its reasonable attorneys' fees and other
costs and expenses incurred, in addition to any other relief to which it may be
entitled, whether or not a lawsuit is filed.

     13. DEFINITIONS

     13.1 DEFINITIONS.

     "AFFILIATE" of a Person is a Person that owns or controls directly or
indirectly the Person, any Person that controls or is controlled by or is under
common control with the Person, and each of that Person's senior executive
officers, directors, partners and, for any Person that is a limited liability
company, that Person's managers and members.

     "BANK EXPENSES" are all audit fees and expenses and reasonable costs or
expenses (including reasonable attorneys' fees and expenses) for preparing,
negotiating, administering, defending and enforcing the Loan Documents
(including appeals or Insolvency Proceedings).

     "BASIC RATE" is, as of the Funding Date, the per annum rate of interest
(based on a year of 360 days) equal to one and one half of one percentage points
(1.50%) above the Prime Rate.

                                       10

<PAGE>

     "BORROWER'S BOOKS" are all Borrower's books and records including ledgers,
records regarding Borrower's assets or liabilities, the Collateral, business
operations or financial condition and all computer programs or discs or any
equipment containing the information.

     "CASH BURN" is the amount that is equal to the greater of (i) the net
decrease in cash for the previous, consecutive four (4) month period or (ii) the
net decrease in cash for the next previous month, multiplied by four (4).

     "CLOSING DATE" is the date of this Agreement.

     "CODE" is the Massachusetts Uniform Commercial Code.

     "COLLATERAL" is the property described on EXHIBIT A.

     "COMMITTED EQUIPMENT LINE" is an Equipment Advance or Equipment Advances of
up to Five Hundred Thousand Dollars ($500,000.00).

     "COMMITMENT TERMINATION DATE" is the date which is nine (9) months from the
Closing Date.

     "CONTINGENT OBLIGATION" is, for any Person, any direct or indirect
liability, contingent or not, of that Person for (i) any indebtedness, lease,
dividend, letter of credit or other obligation of another such as an obligation
directly or indirectly guaranteed, endorsed, co-made, discounted or sold with
recourse by that Person, or for which that Person is directly or indirectly
liable; (ii) any obligations for undrawn letters of credit for the account of
that Person; and (iii) all obligations from any interest rate, currency or
commodity swap agreement, interest rate cap or collar agreement, or other
agreement or arrangement designated to protect a Person against fluctuation in
interest rates, currency exchange rates or commodity prices; but "Contingent
Obligation" does not include endorsements in the ordinary course of business.
The amount of a Contingent Obligation is the stated or determined amount of the
primary obligation for which the Contingent Obligation is made or, if not
determinable, the maximum reasonably anticipated liability for it determined by
the Person in good faith; but the amount may not exceed the maximum of the
obligations under the guarantee or other support arrangement.

     "CREDIT EXTENSION" is each Equipment Advance, or any other extension of
credit by Bank for Borrower's benefit.

     "CURRENT LIABILITIES" are the aggregate amount of Borrower's Total
Liabilities which mature within one (1) year, which shall include, without
limitation, all obligations and liabilities of Borrower to Bank.

     "ELIGIBLE EQUIPMENT" is (a) general purpose computer equipment, office
equipment, test and laboratory equipment, furnishings, and, subject to the
limitations set forth below, and (b) Other Equipment that complies with all of
Borrower's representations and warranties to Bank and which is reasonably
acceptable to Bank in all respects.

     "EQUIPMENT ADVANCE" is defined in Section 2.1.1.

     "EQUIPMENT" is all present and future machinery, equipment, tenant
improvements, furniture, fixtures, vehicles, tools, parts and attachments in
which Borrower has any interest.

     "ERISA" is the Employment Retirement Income Security Act of 1974, and its
regulations.

     "EVENT OF LOSS" is defined in Section 6.8.

     "FINANCED EQUIPMENT" is all present and future Eligible Equipment in which
Borrower has any interest, the purchase of which is financed by an Equipment
Advance.

                                       11

<PAGE>

     "FUNDING DATE" is any date on which an Equipment Advance is made to or on
account of Borrower.

     "GAAP" is generally accepted accounting principles.

     "GUARANTOR" is any present or future guarantor of the Obligations,
including Viacord, Inc, a Delaware corporation.

     "INDEBTEDNESS" is (a) indebtedness for borrowed money or the deferred price
of property or services, such as reimbursement and other obligations for surety
bonds and letters of credit, (b) obligations evidenced by notes, bonds,
debentures or similar instruments, (c) capital lease obligations and (d)
Contingent Obligations.

     "INSOLVENCY PROCEEDING" is any proceeding by or against any Person under
the United States Bankruptcy Code, or any other bankruptcy or insolvency law,
including assignments for the benefit of creditors, compositions, extensions
generally with its creditors, or proceedings seeking reorganization,
arrangement, or other relief.

     "INVESTMENT" is any beneficial ownership of (including stock,
partnership interest or other securities) any Person, or any loan, advance or
capital contribution to any Person.

     "LIEN" is a mortgage, lien, deed of trust, charge, pledge, security
interest or other encumbrance.

     "LOAN AMOUNT" in respect of each Equipment Advance is the original
principal amount of such Equipment Advance.

     "LOAN DOCUMENTS" are, collectively, this Agreement, any note, or notes
executed by Borrower, and any other present or future agreement between Borrower
and/or for the benefit of Bank in connection with this Agreement, all as
amended, extended or restated.

     "LOAN SUPPLEMENT" is defined in Section 2.1.1(b) and attached as EXHIBIT B.

     "MATERIAL ADVERSE CHANGE" is: (i) A material impairment in the perfection
or priority of Bank's security interest in the Collateral or in the value of
such Collateral which is not covered by adequate insurance occurs; or (ii) Bank
determines, based upon information available to it and in its reasonable
judgment, that there is a reasonable likelihood that Borrower shall fail to
comply with one or more of the financial covenants in Section 6 during the next
succeeding financial reporting period;

     "MATURITY DATE" is with respect to each Equipment Advance, the last day of
the Repayment Period for such Equipment Advance, or if earlier, (i) the date of
prepayment and/or (ii) the date of acceleration of such Equipment Advance by
Bank following an Event of Default.

     "OBLIGATIONS" are debts, principal, interest, Bank Expenses and other
amounts Borrower owes Bank now or later, including letters of credit and foreign
exchange contracts, if any, and including interest accruing after Insolvency
Proceedings begin and debts, liabilities, or obligations of Borrower assigned to
Bank.

     "ORIGINAL STATED COST" is (i), the original cost to the Borrower of the
item of new Equipment net of any and all freight, installation, tax, or (ii) the
fair market value assigned to such item of used Equipment by mutual agreement of
Borrower and Bank at the time of making of the Equipment Advance.

     "OTHER EQUIPMENT" is leasehold improvements, intangible property such as
computer software and software licenses, equipment specifically designed or
manufactured for Borrower, other intangible property, limited use property and
other similar property and soft costs approved by the Bank, including sales tax,
freight and installation expenses. Unless otherwise agreed to by Bank, not more
than 25% of the proceeds of the Committed Equipment Line shall be used to
finance Other Equipment.

                                       12

<PAGE>

     "PAYMENT DATE" is defined in Section 2.2(a).

     "PERSON" is any individual, sole proprietorship, partnership, limited
liability company, joint venture, company, trust, unincorporated organization,
association, corporation, institution, public benefit corporation, firm, joint
stock company, estate, entity or government agency.

     "PREPAID INTEREST" is defined in Section 2.2(c).

     "PRIME RATE" is Bank's most recently announced "prime rate," even if it is
not Bank's lowest rate.

     "QUICK ASSETS" is, on any date, the Borrower's consolidated, unrestricted
cash, cash equivalents, net billed accounts receivable and investments with
maturities of less than 12 months determined according to GAAP.

     "REPAYMENT PERIOD," as to each Equipment Advance, is a period of time equal
to thirty six (36) consecutive months commencing on the Funding Date of such
Equipment Advance.

     "RESPONSIBLE OFFICER" is each of the Chief Executive Officer, President,
Chief Financial Officer and Controller of Borrower.

     "SCHEDULE" is any attached schedule of exceptions.

     "SCHEDULED PAYMENT" is defined in Section 2.2(a).

     "SUBORDINATED DEBT" is debt incurred by Borrower subordinated to Borrower's
debt to Bank (pursuant to a subordination agreement entered into between the
Bank, the Borrower and the subordinated creditor).

     "SUBSIDIARY" is for any Person, joint venture, or any other business entity
of which more than 50% of the voting stock or other equity interests is owned or
controlled, directly or indirectly, by the Person or one or more Affiliates of
the Person.

     "TOTAL LIABILITIES" is on any day, obligations that should, under GAAP, be
classified as Liabilities on Borrower's consolidated balance sheet, including
all Indebtedness.

                                       13

<PAGE>

     IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed as a sealed instrument under the laws of the Commonwealth of
Massachusetts as of the date first above written.

BORROWER:

VIACELL, INC.

By: /s/ Marc Beer
   --------------------------------------------------

Name: Marc Beer
     ------------------------------------------------

Title: Chief Executive Officer
      -----------------------------------------------

BANK:

SILICON VALLEY BANK, D/B/A
SILICON VALLEY EAST

By: /s/ Melissa Stepanis
   --------------------------------------------------

Name: Melissa Stepanis
     ------------------------------------------------

Title: Vice President
      -----------------------------------------------

SILICON VALLEY BANK

By: /s/ Signature on File
   --------------------------------------------------

Name: [illegible]
     ------------------------------------------------

Title:  AVP
      -----------------------------------------------
    (Signed in Santa Clara County, California)

                                       14

<PAGE>

                                    EXHIBIT A

         The Collateral consists of all of Borrower's right, title and interest
in and to the following:

         Each item of equipment, or personal property financed with a "Equipment
Advance" pursuant to that certain Loan and Security Agreement, dated as of June
15, 2000 (the "Loan Agreement"), by and between Borrower and Bank, including,
without limitation, the property described in Annex A hereto, whether now owned
or hereafter acquired, together with all substitutions, renewals or replacements
of and additions, improvements, and accessions to any and all of the foregoing,
and all proceeds from sales, renewals, releases or other dispositions thereof.

                                       15

<PAGE>

                              ANNEX A TO EXHIBIT A

         The Financed Equipment being financed with the Equipment Advance is
listed below. Upon the funding of such Equipment Advance, this schedule
automatically shall be deemed to be a part of the Collateral.

Description of Equipment      Make      Model         Serial #         Invoice#

                                       16

<PAGE>

                                    EXHIBIT B

                        FORM OF LOAN AGREEMENT SUPPLEMENT

                        LOAN AGREEMENT SUPPLEMENT No. [1]

         LOAN AGREEMENT SUPPLEMENT No. [1], dated June 15, 2000 ("Supplement"),
to the Loan and Security Agreement dated as of June 15, 2000 (the "Loan
Agreement") by and between the undersigned ViaCell, Inc, ("Borrower"), and
Silicon Valley Bank ("Bank").

         Capitalized terms used herein but not otherwise defined herein are used
with the respective meanings given to such terms in the Loan Agreement.

To secure the prompt payment by Borrower of all amounts from time to time
outstanding under the Loan Agreement, and the performance by Borrower of all the
terms contained in the Loan Agreement, Borrower grants Bank, a first priority
security interest in each item of equipment and other property described in
Annex A hereto, which equipment and other property shall be deemed to be
additional Financed Equipment and Collateral. The Loan Agreement is hereby
incorporated by reference herein and is hereby ratified, approved and confirmed.
Annex A (Equipment Schedule) and Annex B (Loan Terms Schedule) are attached
hereto. The proceeds of the Loan should be transferred to Borrower's account
with Bank set forth below:

         Bank Name:        Silicon Valley Bank
         Account No.:      3300210718

Borrower hereby certifies that (a) the foregoing information is true and correct
and authorizes Bank to endorse in its respective books and records, the Basic
Rate applicable to the Funding Date of the Loan contemplated in this Loan
Agreement Supplement and the principal amount set forth in the Loan Terms
Schedule; (b) the representations and warranties made by Borrower in the Loan
Agreement are true and correct on the date hereof and shall be true and correct
on such Funding Date. No Event of Default has occurred and is continuing under
the Loan Agreement. This Supplement may be executed by Borrower and Bank in
separate counterparts, each of which when so executed and delivered shall be an
original, but all such counterparts shall together constitute but one and the
same instrument.

         This Supplement is delivered as of this day and year first above
written.

SILICON VALLEY BANK                        ViaCell, Inc.

By:                                        By: /s/ Marc Beer
   ---------------------------------          ----------------------------------

     Name:                                    Name: Marc Beer
          --------------------------               -----------------------------

     Title:                                   Title: Chief Executive Officer
           -------------------------                ----------------------------

Annex A - Description of Financed Equipment
Annex B - Loan Terms Schedule

                                       17

<PAGE>

                               SILICON VALLEY BANK

                            INVOICE FOR LOAN CHARGES

BORROWER:                  VIACELL, INC.
LOAN OFFICER:              MELISSA L. STEPANIS, ASSISTANT VICE PRESIDENT
DATE:                       8/22/2000

         Committed Equipment Line Fee                             $  2,500.00

         Other Bank Expenses -

                 (a)   UCC Filing Fees 4 @ $20.00                 $     80.00

                 (b)   Post Filing Searches 2 @ $40.00            $     80.00

         Less Payments Received                                  ($  2,500.00)

         TOTAL FEES DUE                                           $    160.00
         --------------

Please indicate the method of payment:

          { } A check for the total amount is attached.

          {X} Debit DDA ___________ for the total amount.

          { ) Loan proceeds

IN ADDITION TO THE FOREGOING, THE BORROWER HEREBY AGREES TO REIMBURSE THE BANK
FOR ALL COSTS AND EXPENSES INCURRED IN CONNECTION WITH THE LOAN, INCLUDING,
WITHOUT LIMITATION, AUDITS, LEGAL FEES, EXPENSES AND DISBURSEMENTS. THE BANK
WILL PROVIDE BORROWER WITH PRIOR NOTICE OF ALL SUCH DEBITS. ALL DEBITS SHALL BE
CHARGED TO THE FOLLOWING ACCOUNT:

          ( } Debit DDA __________ for the total amount.

          { } Loan proceeds

BORROWER:
VIACELL, INC.

/s/ Melissa Stepanis (per company)
---------------------------------------------
Authorized Signer

/s/ Melissa Stepanis
---------------------------------------------
Silicon Valley Bank (Date)
Account Officer's Signature

                                       18

<PAGE>

                            NEGATIVE PLEDGE AGREEMENT

         This Negative Pledge Agreement is made as of June 15, 2000, by and
between VIACELL, INC. ("Borrower") and SILICON VALLEY BANK, a
California-chartered bank, with its principal place of business at 3003 Tasman
Drive, Santa Clara, California 95054 and with a loan production office located
at Wellesley Office Park, 40 William Street, Suite 350, Wellesley, Massachusetts
02481, doing business under the name "Silicon Valley East" ("Bank").

In connection with, among other documents, the Loan and Security Agreement (the
"Loan Documents") being concurrently executed herewith between Borrower and
Bank, Borrower agrees as follows:

         1.       Except for the granting of licenses or sublicenses by Borrower
                  in the ordinary course of business, Borrower has not, and
                  shall not, sell, transfer, assign, mortgage, pledge, lease,
                  grant a security interest in, or encumber any of Borrower's
                  Intellectual Property (as defined below):

         2.       Borrower has not, and shall not, enter into a negative pledge
                  agreement, or similar agreement, affecting the rights of the
                  Intellectual Property of Borrower with any other party.

         3.       It shall be an event of default under the Loan Documents
                  between Borrower and Bank if there is a breach of any term of
                  this Negative Pledge Agreement.

         4.       As used herein,

                  (a)      "Intellectual Property" means:

                           (i)      Any and all Copyrights;

                           (ii)     Any and all trade secrets, and any and all
                                    intellectual property rights in computer
                                    software and computer software products now
                                    or hereafter existing, created, acquired or
                                    held by Borrower;

                           (iii)    Any and all design rights which may be
                                    available to Borrower now or hereafter
                                    existing, created, acquired or held by
                                    Borrower;

                           (iv)     All Mask Works or similar rights available
                                    for the protection of semiconductor chips;

                           (v)      All Patents;

                           (vi)     Any Trademarks;

                           (vii)    Any and all claims of Borrower for damages
                                    by way of past, present and future
                                    infringements of any of the rights included
                                    above, with the right, but not the
                                    obligation, to sue for and collect such
                                    damages for said use or infringement of the
                                    intellectual property rights identified
                                    above;

                           (viii)   All licenses or other rights to use any of
                                    the Copyrights, Patents, Trademarks, or Mask
                                    Works and all license fees and royalties
                                    arising from such use to the extent
                                    permitted by such license or rights; and

                           (ix)     All amendments, extensions, renewals and
                                    extensions of any of the Copyrights,
                                    Trademarks, Patents, or Mask Works; and

<PAGE>

                           (x)      All proceeds and products of the foregoing,
                                    including without limitation all payments
                                    under insurance or any indemnity or warranty
                                    payable in respect of any of the foregoing.

                  (b)      "Copyrights" means any and all copyright rights,
                           copyright applications, copyright registrations and
                           like protections in each work or authorship and
                           derivative work thereof, whether published or
                           unpublished and whether or not the same also
                           constitutes a trade secret, now or hereafter
                           existing, created, acquired or held by Borrower.

                  (c)      "Mask Works" means all mask work or similar rights
                           available for the protection of semiconductor chips,
                           now owned or hereafter acquired by Borrower;

                  (d)      "Patents" means all patents, patent applications and
                           like protections including without limitation
                           improvements, divisions, continuations, renewals,
                           reissues, extensions and continuations-in-part of the
                           same of Borrower.

                  (e)      "Trademarks" means any trademark and servicemark
                           rights, whether registered or not, of Borrower,
                           applications to register and registrations of the
                           same and like protections, and the entire goodwill of
                           the business of Borrower connected with and
                           symbolized by such trademarks.

         5.       Capitalized terms used but not otherwise defined herein shall
                  have the same meaning as in the Loan Documents.

         6.       The laws of the Commonwealth of Massachusetts shall apply to
                  this Agreement. BORROWER ACCEPTS FOR ITSELF AND IN CONNECTION
                  WITH ITS PROPERTIES, UNCONDITIONALLY, THE NON-EXCLUSIVE
                  JURISDICTION OF ANY STATE OR FEDERAL COURT OF COMPETENT
                  JURISDICTION IN THE COMMONWEALTH OF MASSACHUSETTS IN ANY
                  ACTION, SUIT, OR PROCEEDING OF ANY KIND, AGAINST IT WHICH
                  ARISES OUT OF OR BY REASON OF THIS AGREEMENT; PROVIDED,
                  HOWEVER, THAT IF FOR ANY REASON BANK CANNOT AVAIL ITSELF OF
                  THE COURTS OF THE COMMONWEALTH OF MASSACHUSETTS, BORROWER
                  ACCEPTS JURISDICTION OF THE COURTS AND VENUE IN SANTA CLARA
                  COUNTY, CALIFORNIA.

         7.       This Agreement shall become effective only when it shall have
                  been executed by Borrower and Bank (provided, however, in no
                  event shall this Agreement become effective until signed by an
                  officer of Bank in California).

                                       2
<PAGE>

         EXECUTED as a sealed instrument this 15th day of June, 2000 under the
laws of the Commonwealth of Massachusetts.

                                     BORROWER:

                                     VIACELL, INC.

                                     By: /s/ Marc Beer
                                         --------------------------------------
                                     Name:  Marc Beer
                                            -----------------------------------
                                     Title: Chief Executive Officer
                                            -----------------------------------

                                     BANK:

                                     SILICON VALLEY BANK D/B/A
                                     SILICON VALLEY EAST

                                     By: /s/ Melissa Stepanis
                                         --------------------------------------
                                     Name:  Melissa Stepanis
                                            -----------------------------------
                                     Title: Vice President
                                            -----------------------------------

                                     SILICON VALLEY BANK

                                     By: /s/ Maggie Garcia
                                         --------------------------------------
                                     Name:  Maggie Garcia
                                            -----------------------------------
                                     Title: Documentation Officer
                                            -----------------------------------
                                            (Signed in Santa Clara, California)

                                       3

<PAGE>

                             UNCONDITIONAL GUARANTY

         For and in consideration of the loan by SILICON VALLEY BANK, a
California-chartered bank, with its principal place of business at 3003 Tasman
Drive, Santa Clara, California 95054 and with a loan production office located
at Wellesley Office Park, 40 William Street, Suite 350, Wellesley, Massachusetts
02481, doing business under the name "Silicon Valley East" ("Bank") to VIACELL,
INC., a Delaware corporation ("Borrower"), which loan is made pursuant to a Loan
and Security Agreement between Borrower and Bank over even date herewith (as may
be further amended from time to time, the "Agreement"), the undersigned
guarantor VIACORD, INC., a Delaware corporation with its principal office at 551
Boylston Street, Boston, Massachusetts ("Guarantor"), hereby unconditionally and
irrevocably guarantees the prompt and complete payment of all amounts that
Borrower owes to Bank and performance by Borrower of the Agreement and any other
agreements between Borrower and Bank, as amended from time to time (collectively
referred to as the "Agreements"), in strict accordance with their respective
terms.

         1. If Borrower does not perform its obligations under the Agreements,
Guarantor will immediately pay all amounts due (including, without limitation,
all principal, interest, and fees) and satisfy all Borrower's obligations under
the Agreements.

         2. These obligations are independent of Borrower's obligations and
separate actions may be brought against Guarantor (whether action is brought
against Borrower or whether Borrower is joined in the action). Guarantor waives
benefit of any statute of limitations affecting its liability. Guarantor's
liability is not contingent on the genuineness or enforceability of the
Agreements.

         3. Bank may, without notice to Guarantor and without affecting
Guarantor's obligations under this Guaranty: (a) renew, extend, or otherwise
change the terms of the Agreements; (b) take security for the payment of this
Guaranty or the Agreements; (c) exchange, enforce, waive and release any
security; and (d) apply the security and direct its sale as Bank, in its
discretion, chooses.

         4. Guarantor waives:

                  (a) Any right to require Bank to: (i) proceed against Borrower
         or any other person; (ii) proceed against or exhaust any security; or
         (iii) pursue any other remedy. Bank may exercise or not exercise any
         right or remedy it has against Borrower or any security it holds
         (including the right to foreclose by judicial or non-judicial sale)
         without affecting Guarantor's liability.

                  (b) Any defenses from disability or other defense of Borrower
         or from the cessation of Borrowers liabilities.

                  (c) Any setoff, defense or counterclaim against Bank.

                  (d) Any defense from the absence, impairment or loss of any
         right of reimbursement or subrogation or any other rights against
         Borrower. Until Borrower's obligations to Bank have been paid,
         Guarantor has no right of subrogation or reimbursement or subrogation
         or other rights against Borrower.

                  (e) Any right to enforce any remedy that Bank has against
         Borrower.

                  (f) Any rights to participate in any security held by Bank.

                  (g) Any demands for performance, notices of nonperformance or
         of new or additional indebtedness. Guarantor is responsible for being
         and keeping itself informed of

<PAGE>

         Borrower's financial condition. Unless Guarantor requests particular
         information, Bank has no duty to provide information to Guarantor.

         5. Guarantor acknowledges that, to the extent Guarantor has or may have
rights of subrogation or reimbursement against Borrower for claims arising out
of this Guaranty, those rights may be impaired or destroyed if Bank elects to
proceed against any real property security of Borrower by nonjudicial
foreclosure. That impairment or destruction could, under certain judicial cases
and based on equitable principles of estoppel, give rise to a defense by
Guarantor against its obligations under this Guaranty. Guarantor waives that
defense and any others arising from Bank's election to pursue nonjudicial
foreclosure.

         6. If Borrower becomes insolvent or is adjudicated bankrupt or files a
petition for reorganization or similar relief under the United States Bankruptcy
Code, or if a petition is filed against Borrower and/or any obligation under the
Agreements is terminated or rejected, or any obligation of Borrower is modified
or if Borrower's obligations are avoided Guarantor's liability will not be
affected and its liability will continue. If Bank must return any payment
because of the insolvency, bankruptcy or reorganization of Borrower, Guarantor
or any other guarantor, this Guaranty will remain effective or be reinstated.

         7. Guarantor subordinates any indebtedness of Borrower it holds to
Bank; and Guarantor will collect, enforce and receive payments as Bank's trustee
and will pay Bank those payments without reducing or affecting its liability
under this Guaranty.

         8. Guarantor will pay Bank's reasonable attorneys' fees and other costs
and expenses incurred enforcing this Guaranty. This Guaranty may not be waived,
revoked or amended without Lender's prior written consent. If any provision of
this Guaranty is unenforceable, all other provisions remain effective. This
Guaranty represents the entire agreement among the parties about this guaranty.
No prior dealings, no usage of trade, and no parol or extrinsic evidence may
supplement or vary this Guaranty. Bank may assign this Guaranty. This Guaranty
benefits Bank, its successors and assigns. This Guaranty is in addition to any
other guaranties Bank obtains.

         9. Guarantor represents and warrants that (i) it has taken all action
necessary to authorize execute, deliver and perform this Guaranty; (ii)
execution, delivery and performance of this Guaranty do not conflict with any
organizational documents or agreements to which it is a party; and (iii) this
Guaranty is a valid and binding obligation, enforceable against Guarantor
according to its terms.

         10. Guarantor will do all of the following:

                  (a) Maintain its corporate existence, remain in good standing
         in Delaware, and continue to qualify in each jurisdiction in which the
         failure to qualify could have a material adverse effect on the
         financial condition, operations or business. Maintain all licenses,
         approvals, and agreements, the loss of which could have a material
         adverse effect on its financial condition, operations or business.

                  (b) Comply with all statutes and regulations if non-compliance
         could adversely affect its financial condition, operations or business.

                  (c) Execute other instruments and take action Bank reasonably
         requests to effect the purposes of this Agreement.

         11. This Guaranty is governed by Massachusetts law, without regard to
conflicts of laws. GUARANTOR WAIVES ITS RIGHT TO A JURY TRIAL OF ANY ACTION
ARISING OUT OF THIS

                                       2
<PAGE>

GUARANTY, INCLUDING CONTRACT CLAIMS, TORT CLAIMS, AND ALL OTHER CLAIMS.
Guarantor submits to the exclusive jurisdiction of the State and Federal courts
in Massachusetts.

         IN WITNESS WHEREOF, the undersigned Guarantor has executed this
Guaranty as an instrument under seal under the laws of the Commonwealth of
Massachusetts, as of this 15th day of June, 2000.

                                       ("Guarantor")

                                       VIACORD, INC.

                                       By: /s/ Cynthia A. Fisher
                                           ------------------------------------
                                       Name:  Cynthia A. Fisher
                                              ---------------------------------
                                       Title: President
                                              ---------------------------------
                                              ViaCell, Inc.
                                              President
                                              ViaCord, Inc.

                                       3
<PAGE>

                           LOAN MODIFICATION AGREEMENT

     This Loan Modification Agreement is entered into as of November 2, 2000,
by and between VIACELL, INC. (the "Borrower") and Silicon Valley Bank, a
California-chartered bank doing business in Massachusetts as "Silicon Valley
East" ("Bank").

1.   DESCRIPTION OF EXISTING INDEBTEDNESS. Among other indebtedness which may be
owing by Borrower to Bank, Borrower is indebted to Bank pursuant to, among other
documents, a Loan and Security Agreement, dated June 15, 2000, as may be amended
from time to time, (the "Loan Agreement"). The Loan Agreement provided for,
among other things, a Committed Equipment Line in the original principal amount
of Five Hundred Thousand Dollars ($500,000). Defined terms used but not
otherwise defined herein shall have the same meanings as set forth in the Loan
Agreement.

Hereinafter all indebtedness owing by Borrower to Bank shall be referred to as
the "Indebtedness."

2.   DESCRIPTION OF COLLATERAL. Repayment of the Indebtedness is secured by the
Collateral as described in the Loan Agreement. Additionally, the Committed
Equipment Line is guaranteed by VIACORD, INC. (the "Guarantor") pursuant to a
Unconditional Guaranty agreement (the "Guaranty").

Hereinafter, the above-described security documents and guaranties, together
with all other documents securing repayment of the Indebtedness shall be
referred to as the "Security Documents". Hereinafter, the Security Documents,
together with all other documents evidencing or securing the Indebtedness shall
be referred to as the "Existing Loan Documents".

3.   DESCRIPTION OF CHANGE IN TERMS.

     A.   MODIFICATION(S) TO LOAN AGREEMENT.

     1.   Section 2.1.2 entitled "Term Loan" is hereby incorporated to read as
          follows:

          (a)  Bank shall make a Term Loan available to Borrower,

          (b)  Through January 31, 2001, (the "Term Loan Availability End
               Date"), Bank will make 3 advances (the "Term Loan Advance" and
               collectively, "Term Loan Advances") not exceeding the Term Loan.
               Term Loan Advances outstanding on the Term Loan Availability End
               Date will be payable 12 equal quarterly installments of principal
               plus accrued interest (the "Term Loan Payment"). Each Term Loan
               Payment is payable on the last day of each quarter during the
               term of the loan. Borrower's final Term Loan Payment due on
               January 31, 2004 (the "Term Loan Maturity Date") includes all
               outstanding Term Loan principal and accrued interest.

          (c)  The Term Loan accrues interest at a per annum rate equal to the
               Prime Rate. After an Event of Default, Obligations accrue
               interest at 5 percent above the rate effective immediately before
               the Event of Default. The interest rate increases and decreases
               when the Prime Rate changes. Interest is computed on a 360 day
               year for the actual number of days elapsed.

     2.   Section 4.1 entitled "Grant of Security Interest" is hereby amended in
          part to provide that Borrower shall allow Bank to perfect its security
          interest in Borrower's Certificate of Deposit #8800054341.

     3.   Section 6.6 entitled "Financial Covenants" is hereby amended in part
          to provide that the Financial Covenants under this Section shall apply
          only to the Committed Equipment Line.

<PAGE>

     4.   Exhibit "A" is hereby amended in part to include the following:

          Certificate of Deposit No. 8800054341 in an amount not less than One
          Million Dollars ($1,000,000), together with all renewals and proceeds
          of the foregoing; and

          Borrower and Bank are parties to that certain Negative Pledge
          Agreement, whereby Borrower, in connection with Bank's loan or loans
          to Borrower, has agreed, among other things, not to sell, transfer,
          assign, mortgage, pledge, lease grant a security interest in, or
          encumber any of its Intellectual Property, without Bank's prior
          written consent.

     5.   The following defined terms set forth in Section 13.1 entitled
          "Definitions" are hereby incorporated to read as follows:

          "Credit Extension" is each Equipment Advance, Term Loan, or any other
          extension of credit by Bank for Borrower's benefit.

          "Term Loan Availability End Date" is defined in Section 2.1.2.

          "Term Loan" is a loan of $1,000,000.

          "Term Loan Maturity Date" is defined in Section 2.1.2.

4. CONSISTENT CHANGES. The Existing Loan Documents are hereby amended wherever
necessary to reflect the changes described above.

5. NO DEFENSES OF BORROWER. Borrower agrees that, as of this date, it has no
defenses against the obligations to pay any amounts under the Indebtedness.

6. CONTINUING VALIDITY. Borrower understands and agrees that in modifying the
existing Indebtedness, Bank is relying upon Borrower's representations,
warranties, and agreements, as set forth in the Existing Loan Documents.
Except as expressly modified pursuant to this Loan Modification Agreement,
the terms of the Existing Loan Documents remain unchanged and in full force
and effect. Bank's agreement to modifications to the existing Indebtedness
pursuant to this Loan Modification Agreement in no way shall obligate Bank to
make any future modifications to the Indebtedness. Nothing in this Loan
Modification Agreement shall constitute a satisfaction of the Indebtedness.
It is the intention of Bank and Borrower to retain as liable parties all
makers and endorsers of Existing Loan Documents, unless the party is
expressly released by Bank in writing. Unless expressly released herein, no
maker, endorser, or guarantor will be released by virtue of this Loan
Modification Agreement. The terms of this Paragraph apply not only to this
Loan Modification Agreement, but also to all subsequent loan modification
agreements.

7. JURISDICTION/VENUE. Borrower accepts for itself and in connection with its
properties, unconditionally, the non-exclusive jurisdiction of any state or
federal court of competent jurisdiction in the Commonwealth of Massachusetts
in any action, suit, or proceeding of any kind against it which arises out of
or by reason of this Loan Modification Agreement; provided, however, that if
for any reason Bank cannot avail itself of the courts of the Commonwealth of
Massachusetts, then venue shall lie in Santa Clara County, California.

8. COUNTERSIGNTURE. This Loan Modification Agreement shall become effective
only when it shall have been executed by Borrower and Bank (provided,
however, in no event shall this Loan Modification Agreement become effective
until signed by an officer of Bank in California).

                                       2

<PAGE>

         This Loan Modification Agreement is executed as of the date first
written above.

BORROWER:                                      BANK:

VIACELL, INC.                                  SILICON VALLEY BANK, doing
                                               business as SILICON VALLEY EAST

By: /s/ Marc Beer                              By: /s/ Melissa Stepanis - VP
   -------------------------------                ------------------------------

Name: Marc Beer                                Name: Melissa Stepanis
     -----------------------------                  ----------------------------

Title: CEO                                     Title: Vice President
      ----------------------------                   ---------------------------

                                               SILICON VALLEY BANK

                                               By: /s/ Maggie Garcia
                                                  ------------------------------

                                               Name: Maggie Garcia
                                                    ----------------------------

                                               Title: Loan Administrative Team
                                                      Leader
                                                     ---------------------------
                                              (Signed at Santa Clara County, CA)

The undersigned hereby consent to the modifications to the Indebtedness pursuant
to this Loan Modification Agreement, hereby ratifies all the provisions of the
Guaranty and confirms that all provisions of that document are in full force and
effect.

GUARANTOR

VIACORD, INC.                                  Date: 12/4/00
                                                    ----------------------------

By: /s/ Morey Kraus
   ----------------------------------

Name: Morey Kraus
     --------------------------------

Title: CTO
      -------------------------------

                                       3

<PAGE>

                           LOAN MODIFICATION AGREEMENT

         This Loan Modification Agreement is entered into as of March 9, 2001,
however, effective as of January 31, 2001, by and between VIACELL, INC. (the
"Borrower") and Silicon Valley Bank, a California-chartered bank doing business
in Massachusetts as "Silicon Valley East" ("Bank").

1. DESCRIPTION OF EXISTING INDEBTEDNESS. Among other indebtedness which may be
owing by Borrower to Bank, Borrower is indebted to Bank pursuant to, among other
documents, a Loan and Security Agreement, dated June 15, 2000, as may be amended
from time to time, (the "Loan Agreement"). The Loan Agreement provided for,
among other things, a Committed Equipment Line in the original principal amount
of Five Hundred Thousand Dollars ($500,000). The Loan Agreement was modified,
pursuant to, among other documents, a Loan Modification Agreement dated November
2, 2000, pursuant to which, among other things, a Term Loan in the original
principal amount of One Million Dollars ($1,000,000) was incorporated. Defined
terms used but not otherwise defined herein shall have the same meanings as set
forth in the Loan Agreement.

Hereinafter, all indebtedness owing by Borrower to Bank shall be referred to as
the "Indebtedness."

2. DESCRIPTION OF COLLATERAL. Repayment of the Indebtedness is secured by the
Collateral as described in the Loan Agreement. Additionally, the Committed
Equipment Line is guaranteed by VIACORD, INC. (the "Guarantor") pursuant to a
Unconditional Guaranty agreement (the "Guaranty").

Hereinafter, the above-described security documents and guaranties, together
with all other documents securing repayment of the Indebtedness shall be
referred to as the "Security Documents". Hereinafter, the Security Documents,
together with all other documents evidencing or securing the Indebtedness shall
be referred to as the "Existing Loan Documents".

3. DESCRIPTION OF CHANGE IN TERMS.

         A.       MODIFICATION(S) TO LOAN AGREEMENT.

                  1.       Section 2.1.2 entitled "Term Loan" is hereby amended
                           to read as follows:

                           Through March 15, 2001, (the "Term Loan
                           Availability End Date"), Bank will make 3 advances
                           (the "Term Loan Advance" and collectively, "Term
                           Loan Advances") not exceeding the Term Loan. Term
                           Loan Advances outstanding on the Term Loan
                           Availability End Date will be payable 12 equal
                           quarterly installments of principal plus accrued
                           interest (the "Term Loan Payment"). Each Term Loan
                           Payment is payable on the last day of each quarter
                           during the term of the loan. Borrower's final Term
                           Loan Payment due on March 31, 2004 (the "Term Loan
                           Maturity Date") includes all outstanding Term Loan
                           principal and accrued interest.

4. CONSISTENT CHANGES. The Existing Loan Documents are hereby amended wherever
necessary to reflect the changes described above.

5. NO DEFENSES OF BORROWER. Borrower agrees that, as of this date, it has no
defenses against the obligations to pay any amounts under the Indebtedness.

6. CONTINUING VALIDITY. Borrower understands and agrees that in modifying the
existing Indebtedness, Bank is relying upon Borrower's representations,
warranties, and agreements, as set forth in the Existing Loan Documents. Except
as expressly modified pursuant to this Loan Modification Agreement, the terms of
the Existing Loan Documents remain unchanged and in full force and effect.
Bank's agreement to modifications to the existing Indebtedness pursuant to this
Loan Modification Agreement in no way shall obligate Bank to make any future
modifications to the Indebtedness. Nothing in this Loan Modification Agreement
shall constitute a satisfaction of the Indebtedness. It is the intention of Bank
and Borrower to retain as liable parties all makers and endorsers of Existing
Loan Documents, unless the party is expressly released by Bank in writing.
Unless expressly released herein, no maker, endorser, or guarantor will be

<PAGE>

released by virtue of this Loan Modification Agreement. The terms of this
Paragraph apply not only to this Loan Modification Agreement, but also to all
subsequent loan modification agreements.

7. JURISDICTION/VENUE. Borrower accepts for itself and in connection with its
properties, unconditionally, the non-exclusive jurisdiction of any state or
federal court of competent jurisdiction in the Commonwealth of Massachusetts
in any action, suit, or proceeding of any kind against it which arises out of
or by reason of this Loan Modification Agreement; provided, however, that if
for any reason Bank cannot avail itself of the courts of the Commonwealth of
Massachusetts, then venue shall lie in Santa Clara County, California.

8. COUNTERSIGNATURE. This Loan Modification Agreement shall become effective
only when it shall have been executed by Borrower and Bank (provided, however,
in no event shall this Loan Modification Agreement become effective until signed
by an officer of Bank in California).

         This Loan Modification Agreement is executed as of the date first
written above.

BORROWER:                               BANK:

VIACELL, INC.                           SILICON VALLEY BANK, doing
                                        business as SILICON VALLEY EAST

By: /s/ Marc Beer                       By: /s/ Naomi Herman
   ----------------------------             -----------------------------------

Name: Marc Beer                         Name: Naomi Herman
     --------------------------               ---------------------------------

Title: CEO                              Title: Associate
      -------------------------                --------------------------------

                                        SILICON VALLEY BANK

                                        By: /s/ Maggie Garcia
                                           ------------------------------------

                                        Name: Maggie Garcia
                                             ----------------------------------

                                        Title: Loan Admin.Team Leader
                                              ---------------------------------
                                             (Signed at Santa Clara County, CA)

The undersigned hereby consent to the modifications to the Indebtedness pursuant
to this Loan Modification Agreement, hereby ratifies all the provisions of the
Guaranty and confirms that all provisions of that document are in full force and
effect.

GUARANTOR:

VIACORD, INC.                                        Date: 3/14/01
                                                           --------------------

By: /s/ Morey Kraus
    ---------------------------

Name: Morey Kraus
      -------------------------

Title:
      -------------------------

                                       2
<PAGE>

                      [LOGO] SILICON VALLEY BANK LETTERHEAD

RECEIPT FOR TERM DEPOSIT

Class Code 780 Account Number 8800054341 Interest Rate 4.40% Annual Percentage
Yield 4.40%

Issue Date 12/26/00  Maturity Date  12/21/01  Term  360 days

Amount Deposited               *****$1,000,000.00*****                  Dollars
                 --------------------------------------------------------------

IN THE NAME(S) OF

                  ******Viacell Inc.*******

66A       043244816

INTEREST PAYMENT FREQUENCY

{ } Monthly           { } Quarter       { } Semi-Annually         { } Annually
{X} At Maturity Of The Certificate

METHOD OF INTEREST DISTRIBUTION

{ } Credit To Certificate At Maturity Only  {X} Credit To Acct. No.  3300210718
                                                                    -----------
    TCD HELD FOR COLLATERAL

     X    TRADE            NOTE             CASH      Signature on File
     _   FINANCE         _ DEPT.           _ MGT      -------------------------
                                                      BANK AUTHORIZED SIGNATURE

This Term Deposit is Subject To The Terms And Conditions Hereon And As Specified
On The Signature Card And Agreement On File With Silicon Valley Bank.

TERMS AND CONDITIONS

INTEREST RATE AND PAYMENT - The interest rate for your account will be paid
until the maturity date of your certificate. Interest begins to accrue on the
business day you deposit non-cash items (for example, checks). Interest will
not be compounded. Interest will be credited according to your instructions
at the time your account is opened. The interest payment may be credited to
your certificate at maturity, credited to another account at the Bank, or
paid by cashier's check on either a monthly, quarterly, semi-annual or annual
basis or at maturity of the certificate. However, if the certificate is less
than 31 days, interest will only be credited at maturity. We use the daily
balance method to calculate the interest on your account. This method applies
a daily periodic rate to the principal in the account each day.

ADDITIONAL DEPOSITS - After the account is opened, deposits will only be
accepted on the maturity date or any date within the grace period.

RENEWAL - This account will automatically renew at maturity for a like period at
Silicon Valley Bank's prevailing interest rate for that particular term. You
have a grace period after the maturity date to withdraw the funds without being
charged a penalty. You have a grace period of two (2) business days on a
maturity of a 7-31 day term account. You have a grace period of ten (10)
business days on a maturity of a 32 or more day term account. The Bank reserves
the right to terminate this term deposit during any renewal period upon 10 days
written notice to depositor. If you withdraw your funds during the grace period,
the term deposit will cease earning interest as of the maturity date.

PENALTY FOR EARLY WITHDRAWAL - Partial withdrawals will not be permitted. If we
permit a withdrawal before the maturity date, a penalty as shown below will be
imposed.

a.       Deposits with an original maturity of 31 days or less will forfeit all
         interest earned from the date of deposit. There is a minimum penalty of
         seven (7) days simple interest.

b.       Deposits with an original maturity of 32 days to one year will forfeit
         an amount equal to 31 days simple interest at the interest rate paid on
         the time deposit at the time of withdrawal on the full amount of the
         deposit.

c.       Deposits with an original maturity of more than one year will forfeit
         an amount equal to 90 days simple interest at the interest rate being
         paid on the time deposit at the time of withdrawal on the full amount
         of the deposit.

d.       There is no penalty if early withdrawal is made due to the death of a
         depositor or if the depositor has been declared legally incompetent.

In complying with the terms of this account, it may be necessary to deduct a
portion of the principal deposit to satisfy an early withdrawal penalty.

            PRESENTATION OF THIS RECEIPT IS NECESSARY FOR WITHDRAWAL
                           OF FUNDS FROM THIS ACCOUNT

                        NOT NEGOTIABLE * NOT TRANSFERABLE

<PAGE>

                           LOAN MODIFICATION AGREEMENT

         This Loan Modification Agreement is entered into as of October 24,
2001, by and between VIACELL, INC., (the "Borrower") and Silicon Valley Bank, a
California-chartered bank doing business in Massachusetts as "Silicon Valley
East" ("Bank").

1. DESCRIPTION OF EXISTING INDEBTEDNESS. Among other indebtedness which may be
owing by Borrower to Bank, Borrower is indebted to Bank pursuant to, among other
documents, a Loan and Security Agreement, dated June 15, 2000, as may be amended
from time to time, (the "Loan Agreement"). The Loan Agreement provided for,
among other things, a Committed Equipment Line in the original principal amount
of Five Hundred Thousand Dollars ($500,000). The Loan Agreement was modified,
pursuant to, among other documents, a Loan Modification Agreement dated November
2, 2000, pursuant to which, among other things, a Term Loan in the original
principal amount of One Million Dollars ($1,000,000) was incorporated. Defined
terms used but not otherwise defined herein shall have the same meanings as set
forth in the Loan Agreement.

Hereinafter, all indebtedness owing by Borrower to Bank shall be referred to as
the "Indebtedness."

2. DESCRIPTION OF COLLATERAL. Repayment of the Indebtedness is secured by the
Collateral as described in the Loan Agreement. Additionally, repayment of the
Indebtedness is secured by certificate of deposit number 8800054341. The
Committed Equipment line is guaranteed by VIACORD, INC. (the "Guarantor")
pursuant to a Unconditional Guaranty agreement (the "Guaranty").

Hereinafter, the above-described security documents and guaranties, together
with all other documents securing repayment of the Indebtedness shall be
referred to as the "Security Documents". Hereinafter, the Security Documents,
together with all other documents evidencing or securing the indebtedness
shall be referred to as the "Existing Loan Documents":

3. DESCRIPTION OF CHANGE IN TERMS.

         A.       MODIFICATION(S) TO LOAN AGREEMENT.

                  1.       Section 2.1.3 entitled "Term Loan 2" is hereby
                           incorporated to read as follows:

                           2.1.3    Term Loan 2.

                           (a) Bank shall make Term Loan available to Borrower
                           as follows.

                           (b) Through April 24, 2002, (the "Term Loan 2
                           Availability End Date"), Bank will make up to 2
                           advances (the "Term Loan 2 Advance" and collectively,
                           "Term Loan 2 Advances") not exceeding the Term Loan
                           2. Each Term Loan 2 Advance shall immediately
                           amortize and be payable at Borrower's election (I)
                           in 36 equal monthly installments of principal plus
                           accrued Interest or (II) in 12 equal quarterly
                           installments of principal plus accrued interest
                           beginning 30 days after each Term Loan 2 Advance and
                           continue on the same day of each month thereafter
                           (the "Amortization Period"). The final payment for
                           each Amortization Period will be for all outstanding
                           principal and accrued interest not yet paid and will
                           be due on the applicable Term Loan 2 Maturity Date.
                           Borrower must notify Bank of its decision to request
                           quarterly payment of the payments at the time of the
                           Advance request or such payments shall be due and
                           payable on a monthly basis. Term Loan 2 Advances when
                           repaid may not be reborrowed.

                           (c) The Term Loan 2 accrues interest at a per annum
                           fixed rate equal to the Prime Rate on the date of
                           each Term Loan Advance. After an Event of Default,
                           Obligations accrue interest at 5 percent above the
                           rate effective immediately before the Event of
                           Default. The interest rate increases and decreases
                           when the Prime Rate changes. Interest is computed on
                           a 360 day year for the actual number of days elapsed.

<PAGE>

                  2.       Borrower grants Bank a first protected security
                           interest in Certificates of Deposit Number 8800054341
                           and ____________ to secure the Obligations under the
                           Loan Agreement, together with all renewals and
                           proceeds thereof. The foregoing Certificates of
                           Deposit shall provide for maturities equal to the
                           maturities of the Credit Extensions, but not less
                           than three years.

                  3.       Exhibit "A" is hereby amended in part to include the
                           following as Collateral:

                           Certificates of Deposit Nos. 8800054341 and
                           ______________, together with all renewals and
                           proceeds of the foregoing.

                  4.       The following defined terms as set forth in Section
                           13.1 entitled "Definitions" are hereby incorporated
                           to read as follows:

                           "Amortization Period" is defined in Section 2.1.3.

                           "Credit Extension" is each Equipment Advance, Term
                           Loan, Term Loan 2, or any other extension of credit
                           by Bank for Borrower's benefit.

                           "Term Loan 2 Availability End Date" is defined in
                           Section 2.1.3.

                           "Term Loan 2" is a loan of $350,000.

                           "Term Loan 2 Maturity Date" is a date which is 36
                           months from the beginning of each Amortization Period
                           but not longer than April 24, 2005.

4. CONSISTENT CHANGES. The Existing Loan Documents are hereby amended wherever
necessary to reflect the changes described above.

5. NO DEFENSES OF BORROWER. Borrower agrees that, as of this date, it has no
defenses against the obligations to pay any amounts under the Indebtedness.

6. CONTINUING VALIDITY. Borrower understands and agrees that in modifying the
existing Indebtedness, Bank is relying upon Borrowers representations,
warranties, and agreements, as set forth in the Existing Loan Documents.
Except as expressly modified pursuant to this Loan Modification Agreement,
the terms of the Existing Loan Documents remain unchanged and in full force
and effect. Bank's agreement to modifications to the existing Indebtedness
pursuant to the Loan Modification Agreement in no way shall obligate Bank to
make any future modifications to the Indebtedness. Nothing in this Loan
Modification Agreement shall constitute a satisfaction of the Indebtedness.
It is the intention of Bank and Borrower to retain as liable parties all
makers and endorsers of Existing Loan Documents, unless the party is expressly
released by Bank in writing. Unless expressly released herein, no maker,
endorser, or guarantor will be released by virtue of this Loan Modification
Agreement. The terms of this Paragraph apply not only to this Loan
Modification Agreement, but also to all subsequent loan modification
agreements.

7. CONCERNING REVISED ARTICLES OF THE UNIFORM COMMERCIAL CODE. The Borrower
affirms and reaffirms that notwithstanding the terms of the Security
Documents to the contrary, (i) that the definition of "Code", "UCC" or
"Uniform Commercial Code" as set forth in the Security Documents shall be
deemed to mean and refer to "the Uniform Commercial Code as adopted by THE
COMMONWEALTH OF MASSACHUSETTS (PRESENTLY MASS. GEN. LAWS CH. 106), may be
amended and in effect from time to time and (ii) the Collateral shall
include, without limitation, the following categories of assets as defined in
the Code: equipment and any accessions thereto), supporting obligations and
any and all proceeds of any thereof, wherever located, whether now owned or
hereafter acquired.

8. JURISDICTION/VENUE. Borrower accepts for itself and in connection with its
properties, unconditionally, the non-exclusive jurisdiction of any state or
federal court of competent jurisdiction in the

                                       2

<PAGE>

Commonwealth of Massachusetts in any action, suit, or proceeding of any kind
against it which arises out of or by reason of this Loan Modification Agreement;
provided, however, that if for any reason Bank cannot avail itself of the courts
of the Commonwealth of Massachusetts then venue shall lie in Santa Clara County,
California.

9. COUNTERSIGNATURE. This Loan Modification Agreement shall become effective
only when it shall have been executed by Borrower and Bank (provided, however,
in no event shall this Loan Modification Agreement become effective until signed
by an officer of Bank in California).

         This Loan Modification Agreement is executed as of the date first
written above.

BORROWER:                               BANK:

VIACELL, INC.                           SILICON VALLEY BANK, doing
                                        business as SILICON VALLEY EAST

By: /s/ Mary Thistle                    By: /s/ Jeff Bochman
   ----------------------------             -----------------------------------

Name: Mary Thistle                      Name: Jeff Bochman
     --------------------------               ---------------------------------

Title: VP Finance                       Title: Assistant VP
      -------------------------                --------------------------------

                                        SILICON VALLEY BANK

                                        By: /s/ Maggie Garcia
                                           ------------------------------------

                                        Name: Maggie Garcia
                                             ----------------------------------

                                        Title: Loan Admin.Team Leader
                                              ---------------------------------
                                             (Signed at Santa Clara County, CA)

The undersigned hereby consent to the modifications to the Indebtedness pursuant
to this Loan Modification Agreement, hereby ratifies all the provisions of the
Guaranty and confirms that all provisions of that document are in full force and
effect.

GUARANTOR:

VIACORD, INC.                                        Date:_____________________

By: /s/ Morey Kraus
    ---------------------------

Name: Morey Kraus
      -------------------------

Title: VP
      -------------------------

                                       3<PAGE>
                                                                   Exhibit 10.23

                                LICENSE AGREEMENT

         THIS AGREEMENT, effective as of January 18, 2001 ("EFFECTIVE DATE")
between THE GENERAL HOSPITAL CORPORATION, a not-for-profit corporation doing
business as Massachusetts General Hospital, having a place of business at Fruit
Street, Boston, Massachusetts 02114 ("GENERAL") and CEREBROTEC, INC., a
corporation having offices at 38 Broadway, Suite 313, Everett, MA 02149-2419
("CEREBROTEC").

         WHEREAS, under research programs funded by the GENERAL, the Children's
Medical Center Corporation ("CMCC") and the U.S. Government, the GENERAL and
CMCC through research conducted by Dr. Seth Finklestein and his colleagues,
including Dr. Evan Snyder of CMCC, has developed inventions pertaining to
treatments to enhance recovery from stroke;

         WHEREAS, GENERAL has filed U.S. and foreign Patent Applications
covering said inventions and all Dr. Finklestein's and his colleagues' rights,
title and interest in said applications have been assigned to GENERAL, except
that all Dr. Evan Snyder's rights, title and interest in certain JOINT PATENT
RIGHTS (as defined hereinbelow) have been assigned to CMCC, and that certain
other JOINT PATENT RIGHTS relating to the patent application filed October 27,
2000, serial number to be assigned, which is identified as MGH 1744.0, is
jointly owned by GENERAL and ViaCell, Inc.;

         WHEREAS, GENERAL represents to the best of its knowledge and belief
that, except as recited in the preceding paragraph, it is the owner of all
rights, title and interest in said patent applications and has the right and
ability to grant the license hereinafter described;

         WHEREAS, GENERAL and CMCC have entered into an Inter-Institutional
Agreement, effective January 18, 2001, under which CMCC has granted GENERAL the
right to grant licenses under CMCC's rights in certain JOINT PATENT RIGHTS (as
defined hereinbelow) on CMCC's behalf;

         WHEREAS, as a center for research and education, GENERAL and CMCC are
interested in licensing PATENT RIGHTS and JOINT PATENT RIGHTS and thus
benefiting the public and the GENERAL by facilitating the dissemination of the
results of its research in the form of useful products, but is without capacity
to commercially develop, manufacture, and distribute any such product; and

         WHEREAS, CEREBROTEC having such capacity, desires to commercially
develop, manufacture, use and distribute such products throughout the world;

         NOW THEREFORE, in consideration of the premises and of the faithful
performance of the covenants herein contained, the parties hereto agree as
follows:

                                 1. DEFINITIONS

         1.1      The term "ACCOUNTING PERIOD" shall mean each six month period
ending June 30 and December 31.

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
         1.2      The term "AFFILIATE" with respect to CEREBROTEC shall mean any
corporation or other legal entity controlling, controlled by or under common
control with CEREBROTEC. The term "AFFILIATE" with respect to GENERAL or CMCC
shall mean any company controlling, controlled by, or under common control with
GENERAL or CMCC, respectively. The term "control" means possession, direct or
indirect, of the powers to direct or cause the direction of the management and
policies of an entity, whether through the ownership of voting securities, by
contract or otherwise.

         1.3      The term "FIRST COMMERCIAL SALE" shall mean in each country
the first sale of any PRODUCT by CEREBROTEC, its AFFILIATES or SUBLICENSEES.

         1.4      The term "LICENSE FIELD" shall mean the diagnosis, treatment
or prevention of human and animal diseases.

         1.5      The Term "NET SALES PRICE" shall mean the GROSS SALES PRICE as
defined in (b) below received by CEREBROTEC or any of its AFFILIATES or
SUBLICENSEES ("SELLERS") for the sale or distribution of any PRODUCT to a final
customer who will be the end user of the PRODUCT and is not an AFFILIATE or
SUBLICENSEE ("CUSTOMER"), less (to the extent appropriately documented) the
following amounts actually paid out by CEREBROTEC, its AFFILIATE or SUBLICENSEE
or credited against the amounts received by them from the sale or distribution
of PRODUCT:

                  (a)      (i)      credits and allowances for price adjustment,
rejection, or return of PRODUCTS previously sold;

                           (ii)     rebates and cash discounts to purchasers
allowed and taken;

                           (iii)    amounts for transportation, insurance,
handling or shipping charges to purchasers;

                           (iv)     taxes, duties and other governmental charges
levied on or measured by the sale of PRODUCTS, whether absorbed by CEREBROTEC or
paid by the purchaser so long as CEREBROTEC's price is reduced thereby, but not
franchise or income taxes of any kind whatsoever;

                           (v)      for any sale in which the United States
government on the basis of its royalty-free license pursuant to 35 USC Sec.
202(c) to any PATENT RIGHT requires that the GROSS SALES PRICE of any PRODUCT
subject to such PATENT RIGHT be reduced by the amount of such royalty owed
GENERAL pursuant to paragraph 3.1, the amount of such royalty.

                  (b)      For any bona fide sale to a bona fide CUSTOMER by
CEREBROTEC or any of its AFFILIATES or SUBLICENSEES, the GROSS SALES PRICE
shall be the gross billing price of the PRODUCT.

                  (c)      If CEREBROTEC or any of its AFFILIATES or
SUBLICENSEES sell any PRODUCT in a bona fide sale as a component of a
combination of active functional elements, the GROSS SALES PRICE of the PRODUCT
shall be determined by multiplying the

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
GROSS SALES PRICE of the combination by the fraction A over A+B, in which "A" is
the GROSS SALES PRICE of the PRODUCT portion of the combination when sold
separately during the ACCOUNTING PERIOD in the country in which the sale was
made, and "B" is the GROSS SALES PRICE of the other active elements of the
combination sold separately during said ACCOUNTING PERIOD in said country. In
the event that no separate sale of either such PRODUCT or active elements of the
combination is made during said ACCOUNTING PERIOD in said country, the GROSS
SALES PRICE of the PRODUCT shall be determined by multiplying the GROSS SALES
PRICE of such combination by the fraction C over C+D, in which "C" is the
standard fully-absorbed cost of the PRODUCT portion of such combination, and "D"
is the sum of the standard fully-absorbed costs of the other active elements
component(s), such costs being arrived at using the standard accounting
procedures of CEREBROTEC which will be in accord with generally accepted
accounting practices.

                  (d)      If a SELLER commercially uses or disposes of any
PRODUCT by itself (as opposed to a use or disposition of the PRODUCT as a
component of a combination of active functional elements) other than in a bona
fide sale to a bona fide CUSTOMER, the GROSS SALES PRICE hereunder shall be the
price which would be than payable in an arm's length transaction with such a
CUSTOMER. If a SELLER commercially uses or disposes of any PRODUCT as a
component of a combination of active functional elements other than in a bona
fide sale to a bona fide customer, the GROSS SALES PRICE of the PRODUCT shall be
determined in accordance with paragraph (c) above, using as the GROSS SALES
PRICE of the combination that price which would be then payable in an arm's
length transaction.

                  (e)      Transfer of a PRODUCT within CEREBROTEC or between
CEREBROTEC and an AFFILIATE for sale by the transferee shall not be considered a
sale, commercial use or disposition for the purpose of the foregoing paragraphs;
in the case of such transfer the GROSS SALES PRICE shall be based on sale of the
PRODUCT by the transferee.

         1.6.     The term "OPTION AGREEMENT" shall mean that certain Option
Agreement pertaining to subject matter of this Agreement and to certain of the
patent applications licensed to CEREBROTEC hereunder, that is one of two Option
Agreements between GENERAL and CEREBROTEC dated August 12, 1999.

         1.7.     The term "PATENT RIGHT" shall mean the U.S. Patent
Applications filed by [*] listed on Appendix A, or the equivalent of such
application, including any division, continuation or any foreign patent
application or Letters Patent of the equivalent thereof issuing thereon or
reissue, reexamination or extension thereof. PATENT RIGHTS shall also include
those claims in any continuation-in-part of the aforementioned patent
application which claim an invention described or claimed in said patent
application.

         1.8      The term "JOINT PATENT RIGHT" shall mean [*] or the equivalent
of such applications, including any division, continuation, substitute or any
foreign patent application or Letters Patent or the equivalent

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
thereof issuing thereon or reissue, reexamination or extension thereof. JOINT
PATENT RIGHT shall also include those claims in any continuation-in-part of the
aforementioned patent application which claim an invention described or claimed
in said patent application.

         1.9      The term "PRODUCT" shall mean any article, device,
composition, method or service, the manufacture, use, or sale of which

                  (a)      absent the licenses granted herein, would infringe a
VALID CLAIM of any PATENT RIGHT, or

                  (b)      does not infringe a VALID CLAIM of any PATENT RIGHT
licensed to CEREBROTEC hereunder but the discovery, development, manufacture or
use of which employs TECHNOLOGICAL INFORMATION.

         1.10     The term "SUBLICENSEE" shall mean any non-AFFILIATE third
party granted a license by CEREBROTEC or by an AFFILIATE to make, have made, use
or sell any PRODUCT. As used in this Agreement, "SUBLICENSEE" shall include,
without limitation, any third party to whom CEREBROTEC or an AFFILIATE has
granted, directly or indirectly, the fight to distribute a PRODUCT, provided
that such third party has the responsibility in whole or in part for marketing
and/or promotion of the PRODUCT within the territory for which such distribution
rights are granted.

         1.11     The term "SUBLICENSE REVENUE" shall mean any payments that
CEREBROTEC receives from a SUBLICENSEE in consideration of the sublicense of the
rights granted to CEREBROTEC under Article 2 including, without limitation,
license fees, milestone payments and license maintenance fees, but excluding the
following payments: (a) royalties on NET SALES by the SUBLICENSEE for which
GENERAL receives its royalties pursuant to paragraph 5.1, (b) payments made in
consideration of the issuance of equity or debt securities of CEREBROTEC at fair
market value, and (c) payments specifically committed to the research or
development of PRODUCTS actually conducted by or for CEREBROTEC.

         1.12     The term "TECHNOLOGICAL INFORMATION" shall mean any research
data, designs, formulas, process information, clinical data and other
information pertaining to any invention claimed in PATENT RIGHT which is known
to Dr. Finklestein on the EFFECTIVE DATE.

         1.13     The term "VALID CLAIM" shall mean any claim of any PATENT
RIGHT that has not been (i) finally rejected or (ii) declared invalid by a
patent office or court of competent jurisdiction in any unappealed and
unappealable decision.

         1.14     The term "FINANCING" shall mean either (i) the sale by
CEREBROTEC of securities, which sales generate gross aggregate cash proceeds to
CEREBROTEC, in one or more closings, of at least $1,000,000 (ii) any sale of a
majority of the outstanding shares of CEREBROTEC to a third party regardless of
the amount of CEREBROTEC's compensation, or (iii) the merger or acquisition of
CEREBROTEC with a third party regardless of whether CEREBROTEC's compensation
for such sale is in cash and regardless of the amount of CEREBROTEC's
compensation.

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
         1.15     The term "CLOSING OF THE FINANCING" shall mean the closing of
either (i) the particular round of the FINANCING which results in the gross
aggregate cash proceeds to CEREBROTEC of all rounds of the FINANCING closed to
that date being at least $1,000,000, (ii) the sale of a majority of shares of
CEREBROTEC to a third party, or (iii) the merger or acquisition of CEREBROTEC
with a third party.

                                   2. LICENSE

         2.1      GENERAL hereby grants CEREBROTEC, to the extent not prohibited
by the Untied States Government or by contractual obligations to any other
sponsor of research at GENERAL or CMCC;

                  (a)      an exclusive, worldwide, royalty-bearing license in
the LICENSE FIELD under GENERAL's and CMCC's rights in PATENT RIGHTS and JOINT
PATENT RIGHTS to make, have made, use and sell PRODUCTS;

                  (b)      to the extent an exclusive license is not available
to CEREBROTEC in a country, due to legal or regulatory action in such country, a
non-exclusive, royalty-bearing license in the LICENSE FIELD under PATENT RIGHTS
and JOINT PATENT RIGHTS to make, have made, use and sell PRODUCTS;

                  (c)      the right to sublicense PATENT RIGHTS and JOINT
PATENT RIGHTS exclusively licensed to CEREBROTEC.

         The above licenses to sell PRODUCTS include the right to grant to the
purchaser of products from CEREBROTEC, its AFFILIATES, and SUBLICENSEES the
right to use such purchased PRODUCTS in a method coming within the scope of
PATENT RIGHT.

         2.2      It is understood that the granting of any license hereunder is
subject to GENERAL's and GENERAL's AFFILIATES' right to make and to use the
subject matter described and claimed in all PATENT RIGHTS and JOINT PATENT
RIGHTS, and CMCC's and CMCC's AFFILIATES' right to make and to use the subject
matter claimed in JOINT PATENT RIGHT for research, clinical and educational
purposes but for no other purpose, and that if federal funding supported any
PATENT RIGHT, CEREBROTEC's license will be subject to the rights, conditions and
limitations imposed by U.S. law including without limitation the royalty-free
non-exclusive license granted to the U.S. government (see 35 U.S.C. Section 202
et. seq. and regulations pertaining thereto).

         2.3      Within three (3) months of EFFECTIVE DATE, upon request by
CEREBROTEC, GENERAL shall disclose to CEREBROTEC, TECHNOLOGICAL INFORMATION
which CEREBROTEC will be entitled to use to the extent such use does not
infringe any patent not licensed to CEREBROTEC hereunder.

         2.4      It is understood that nothing herein shall be construed to
grant CEREBROTEC a license express or implied under any patent owned solely or
jointly by GENERAL or CMCC other that the PATENT RIGHTS and JOINT PATENT RIGHTS
expressly licensed hereunder.

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
                          3. DUE DILIGENCE OBLIGATIONS

         3.1      CEREBROTEC shall itself, or through its AFFILIATES or
SUBLICENSEES, use its best efforts to develop and make commercially available
PRODUCTS for commercial sales and distribution throughout the world in the
LICENSE FIELD. Such efforts shall include the following: within twenty-four (24)
months after the EFFECTIVE DATE, achieving either (i) the CLOSING OF THE
FINANCING; or (ii) entering into a partnering agreement with a SUBLICENSEE under
which said SUBLICENSEE agrees to fund research or product development at
CEREBROTEC in an amount of at least [*] for at least two years.

         Within twenty-four (24) months following the EFFECTIVE DATE, GENERAL
and CEREBROTEC shall meet to: (i) agree either to adopt further time-limited
performance objectives, or to adopt amendments to the annual minimum payments
specified in paragraph 5.5, to ensure that CEREBROTEC uses its best efforts to
develop and make commercially available PRODUCTS based on PATENT RIGHTS and
JOINT PATENT RIGHTS for commercial sales and distribution throughout the world;
and (ii) identify such objectives in the event of their necessity. Such
objectives may include requirements such as taking the following steps within
defined timeframes; to complete all animal toxicity tests required in connection
with securing U.S. Food and Drug Administration approval of clinical evaluations
thereof; to initiate and thereafter diligently pursue clinical evaluations of a
PRODUCT and in connection therewith take all actions reasonably necessary under
the Food, Drug and Cosmetic Act (21 USC 301-391); to introduce PRODUCT on a
worldwide basis.

         Provided, however, that GENERAL shall not unreasonably withhold its
consent to any revision in any time periods specified herein or established in
accordance with this paragraph 3.1 whenever requested in writing by CEREBROTEC
and supported by evidence of technical difficulties or delays that the parties
could not have reasonably avoided. Failure to achieve any objective within the
above stated time periods, or within the time periods established in accordance
with this paragraph 3.1 or within any extension granted by GENERAL shall result
in GENERAL having the right to cancel upon thirty (30) days notice any exclusive
license granted hereunder or convert any exclusive license to a non-exclusive
license.

         3.2      At intervals no longer than every six (6) months, CEREBROTEC
shall report in writing to GENERAL on progress made toward the development and
commercialization of PRODUCTS.

             4. FILING, PROSECUTION AND MAINTENANCE OF PATENT RIGHTS
                             AND JOINT PATENT RIGHTS

         4.1      (a)      GENERAL shall be responsible for the preparation,
filing, prosecution and maintenance of all patent applications and patents
included in PATENT RIGHTS and JOINT PATENT RIGHTS, at CEREBROTEC's expense.
GENERAL shall control patent prosecution of all PATENT RIGHTS and JOINT PATENT
RIGHTS using outside patent counsel acceptable to CEREBROTEC in such countries
as CEREBROTEC shall reasonably specify.

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
                  (b)      CEREBROTEC shall reimburse GENERAL for all reasonable
costs for the preparation, filing, prosecution and maintenance of all PATENT
RIGHTS and JOINT PATENT RIGHTS ("Costs") incurred by GENERAL prior to January 1,
2001 (exclusive of Costs previously reimbursed by CEREBROTEC under the Option
Agreements) ("PAST PATENT COSTS"), to be payable upon the CLOSING OF THE
FINANCING, however, if the CLOSING OF THE FINANCING has not occurred by the
first anniversary of the EFFECTIVE DATE, CEREBROTEC shall pay GENERAL [*] of the
PAST PATENT COSTS on said first anniversary and shall pay the balance of said
amount upon the earlier of the CLOSING OF THE FINANCING or the second
anniversary of the EFFECTIVE DATE. PAST PATENT COSTS are estimated at [*],
however, GENERAL shall provide CEREBROTEC with an accounting of these costs,
supported by appropriate documentation, within sixty (60) days of the execution
of this Agreement (but in no event later than the first invoice to be provided
to CEREBROTEC under subparagraph (c) below), and the total costs supported by
such accounting and documentation shall be considered the amount of PAST PATENT
COSTS to be reimbursed by CEREBROTEC in accordance with this paragraph 4.1(b).

                  (c)      Subject to paragraph 4.2, CEREBROTEC shall reimburse
GENERAL for all Costs incurred by GENERAL from and after January 1, 2001, within
thirty (30) days of receipt of invoices from GENERAL or its outside counsel as
contemplated herein.

         4.2      With respect to any PATENT RIGHT, each document or a draft
thereof pertaining to the filing, prosecution, or maintenance of such PATENT
RIGHT, including but not limited to each patent application, office action,
response to office action, request for terminal disclaimer, and request for
reissue or reexamination of any patent issuing from such application shall be
provided to CEREBROTEC as follows. Documents received from any patent office or
counsel's analysis thereof shall be provided promptly after receipt. For a
document to be filed in any patent office, a draft of such document shall be
provided sufficiently prior to its filing, to allow for review and comment by
CEREBROTEC. CEREBROTEC shall have the right to participate in, comment upon and
make recommendations regarding the course of patent prosecution, which
recommendations GENERAL agrees to follow except to the extent such
recommendations result, in GENERAL's determination, in an unwarranted narrowing
of PATENT RIGHTS and/or JOINT PATENT RIGHTS.

         4.3      If CEREBROTEC shall elect not to pay or continue to pay the
Costs for any PATENT RIGHT, CEREBROTEC shall so notify GENERAL promptly and
CEREBROTEC shall thereafter be relieved of the obligation to pay any additional
Costs regarding such PATENT RIGHT incurred after the receipt of such notice by
GENERAL. Such U.S. or foreign patent application or patent shall thereupon cease
to be a PATENT RIGHT hereunder and GENERAL shall be free to prosecute or
maintain such PATENT RIGHT at its own expense and to license its rights to that
particular PATENT RIGHT to any other party on any terms.

                                   5. PAYMENTS

         5.1      Royalties. Beginning with the FIRST COMMERCIAL SALE in any
country, on all sales of PRODUCTS anywhere in the world by CEREBROTEC, its
AFFILIATES or SUBLICENSEES, CEREBROTEC shall pay GENERAL royalties in accordance
with the following schedule, such undertaking and schedule having been agreed to
for the purpose of

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
reflecting and advancing the mutual convenience of the parties. For each PRODUCT
sold by CEREBROTEC or its AFFILIATES and SUBLICENSEES;

                  (a)      [*] of the NET SALES PRICE so long as the PRODUCT,
its manufacture, use or sale is converted by a VALID CLAIM of any PATENT RIGHT
licensed exclusively to CEREBROTEC;

                  (b)      [*] of the NET SALES PRICE whenever the PRODUCT, its
manufacture, use or sale is covered by a VALID CLAIM of any PATENT RIGHT
licensed non-exclusively to CEREBROTEC in the country in question; and

                  (c)      During each of the ten (10) years next following the
FIRST COMMERCIAL SALE anywhere in the world by CEREBROTEC, its AFFILIATES or
SUBLICENSEES, [*] of the NET SALES PRICE of PRODUCT on which no royalty is
payable under paragraph 5.1(a) or 5.1(b) above.

         5.2      (a)      In the event that more than one royalty rate under
paragraph 5.1 is applicable to a PRODUCT, the highest of the applicable
royalties shall apply.

                  (b)      Only one royalty under paragraph 5.1 shall be due and
payable to GENERAL by CEREBROTEC for any PRODUCT regardless of the number of
PATENT RIGHTS and/or JOINT PATENT RIGHTS covering such PRODUCT.

                  (c)      In the event CEREBROTEC determines that it is
necessary to license any technology of a third party in order to make, use or
sell PRODUCTS, then the royalty payment due to GENERAL under Section 5.1(a)
shall be reduced by fifty percent (50%) of the royalties paid by CEREBROTEC
under such third party licenses; provided, however, that in no event shall the
royalty payable to GENERAL under Section 5.1(a) be reduced by more than fifty
percent (50%) in any ACCOUNTING PERIOD.

                  (d)      If any license granted pursuant to Article 2 shall be
or become non-exclusive and GENERAL shall license any PATENT RIGHT to another
licensee for the purpose of making, using or selling PRODUCTS and accept a
royalty or royalties more favorable to such licensee than herein provided for
CEREBROTEC, GENERAL shall give written notice thereof to CEREBROTEC and as of
the EFFECTIVE DATE of such more favorable royalty or royalties, CEREBROTEC's
obligation hereunder to pay royalty or royalties to GENERAL shall be revised to
the more favorable rate.

                  (e)      In the event that the royalty paid to GENERAL is a
significant factor in the return realized by CEREBROTEC so as to diminish
CEREBROTEC's capability to respond to competitive pressures in the market,
GENERAL agrees to consider a reasonable reduction in the royalty paid to GENERAL
as to each such PRODUCT for the period during which such market condition
exists. Factors determining the size of the reduction will include profit margin
on PRODUCT and on analogous products, prices of competitive products, total
prior sales by CEREBROTEC, and CEREBROTEC's expenditures in PRODUCT development.

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
         5.3      Sublicensee Revenue. Subject to Section 5.4, CEREBROTEC shall
pay GENERAL [*] of all SUBLICENSEE REVENUE received by CEREBROTEC. Such payments
shall be due and payable within sixty (60) days after CEREBROTEC receives the
relevant payment from the SUBLICENSEE.

         5.4      Milestones. CEREBROTEC shall pay GENERAL the following amounts
upon the occurrence of the following milestones:

                  (a)      upon commencement of the first Phase III clinical
trial of a PRODUCT by CEREBROTEC or an AFFILIATE or SUBLICENSEE: the greater of
(i) [*] or (ii) [*] of any SUBLICENSEE REVENUE received by CEREBROTEC
attributable to the commencement of the first Phase III clinical trial of such
PRODUCT;

                  (b)      upon filing with the FDA of the first NDA, 510(k),
PMA or PMA Supplement, or comparable application with respect to a PRODUCT by
CEREBROTEC or an AFFILIATE or SUBLICENSEE: the greater of (i) [*] or (ii) [*] of
any SUBLICENSEE REVENUE received by CEREBROTEC attributable to the filing with
the FDA of the first NDA, 510(k), PMA or PMA Supplement, or comparable
application with respect to such PRODUCT; and

                  (c)      upon approval by the FDA of the first NDA, 510(k),
PMA or PMA Supplement, or comparable application with respect to a PRODUCT by
CEREBROTEC or an AFFILIATE or SUBLICENSEE: the greater of (i) [*] or (ii) [*] of
any SUBLICENSEE REVENUE received by CEREBROTEC attributable to the approval by
the FDA of the first NDA, 510(k), PMA or PMA Supplement, or comparable
application with respect to such PRODUCT.

         5.5      Annual Minimum Royalty. CEREBROTEC shall pay GENERAL an annual
minimum royalty of [*] per calendar year, commencing with the calendar year
ending December 31, 2001. Said annual minimum royalty shall increase to [*] per
calendar year, commencing with the calendar year ending December 31, 2004, and
to [*] per calendar year, commencing with the calendar year ending December 31,
2008. The annual minimum royalty payment for each year shall be due within
thirty days of the end of such year, and CEREBROTEC may credit the annual
minimum royalty in each year against any payments otherwise due GENERAL under
this Article 5 for such calendar year.

         5.6      The payments due under this Agreement shall, if overdue, bear
interest until payment at a per annum rate equal to one percent (1%) above the
prime rate in effect at the Fleet Bank on the due date, not to exceed the
maximum permitted by law. The payment of such interest shall not preclude
GENERAL from exercising any other rights it may have as a consequence of the
lateness of any payment.

                             6. REPORTS AND PAYMENTS

         6.1      CEREBROTEC shall keep, and shall cause each of its AFFILIATES
and SUBLICENSEES, if any, to keep full and accurate books of accounts containing
all particulars that may be necessary for the purpose of calculating all
royalties payable to GENERAL. Such

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
books of accounts shall be kept at their principal place of business and, with
all necessary supporting data shall, during all reasonable times for the three
(3) years next following the end of the calendar year to which each shall
pertain be open for inspection at reasonable times by GENERAL or its designee at
GENERAL's expense for the purpose of verifying royalty statements or compliance
with this Agreement.

         6.2      In each year the amount of royalty due shall be calculated
semiannually as of the end of each ACCOUNTING PERIOD and shall be paid
semiannually within the sixty (60) days next following such date, every such
payment to be supported by the accounting prescribed in paragraph 6.3 and to be
made in United States currency. Whenever conversion from any foreign currency
shall be required, such conversion shall be at the rate of exchange thereafter
published in the Wall Street Journal for the business day closest to the end of
the applicable ACCOUNTING PERIOD.

         6.3      With each semiannual payment, CEREBROTEC shall deliver to
GENERAL a full and accurate accounting to include at least the following
information:

                  (a)      Quantity of each PRODUCT sold or leased (by country)
by CEREBROTEC, and its AFFILIATES or SUBLICENSEES;

                  (b)      Total billings for each PRODUCT (by country);

                  (c)      Quantities of each PRODUCT used by CEREBROTEC and its
AFFILIATES or SUBLICENSEES;

                  (d)      Names and addresses of all SUBLICENSEES of
CEREBROTEC; and

                  (e)      Total royalties payable to GENERAL.

                                 7. INFRINGEMENT

         7.1      GENERAL will protect its PATENT RIGHTS and JOINT PATENT RIGHTS
from infringement and prosecute infringers when, in its sole judgement, such
action may be reasonably necessary, proper and justified.

         7.2      If CEREBROTEC shall have supplied GENERAL with written
evidence demonstrating to GENERAL'S reasonable satisfaction prima facie
infringement of a claim of a PATENT RIGHT in the LICENSE FIELD by a third party,
CEREBROTEC may by notice request GENERAL to take steps to protect the PATENT
RIGHT. GENERAL shall notify CEREBROTEC within three (3) months of the receipt of
such notice whether GENERAL intends to prosecute the alleged infringement. If
GENERAL notifies CEREBROTEC that it intends to so prosecute, GENERAL shall,
within three (3) months of its notice to CEREBROTEC either (i) cause
infringement to terminate or (ii) initiate legal proceedings against the
infringer. In the event GENERAL notifies CEREBROTEC that GENERAL does not intend
to prosecute said infringement CEREBROTEC may, upon notice to GENERAL, initiate
legal proceedings against the infringer at CEREBROTEC's expense and in GENERAL's
name if so required by law. No settlement, consent judgment or other voluntary
final disposition of the

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
suit which invalidates or restricts the claims of such PATENT RIGHTS and/or
JOINT PATENT RIGHTS may be entered into without the consent of GENERAL, which
consent shall not be unreasonable withheld. CEREBROTEC shall indemnify GENERAL
against any order for payment that may be made against GENERAL in such
proceedings.

         7.3      In the event one party shall initiate or carry on legal
proceedings to enforce any PATENT RIGHT against any alleged infringer, the other
party shall fully cooperate with and supply all assistance reasonably requested
by the party initiating or carrying on such proceedings. The party which
institutes any suit to protect or enforce a PATENT RIGHT shall have sole control
of that suit and shall bear the reasonable expenses (excluding legal fees)
incurred by said other party in providing such assistance and cooperation as is
requested pursuant to this paragraph. The party initiating or carrying on such
legal proceedings shall keep the other party informed of the progress of such
proceedings and said other party shall be entitled to counsel in such
proceedings but at its own expense. Any award paid by third parties as the
result of such proceedings (whether by way of settlement or otherwise) shall
first be applied to reimbursement of the unreimbursed legal fees and expenses
incurred by either party and then the remainder shall be divided between the
parties as follows:

                  (a)      (i)      If the amount is based on lost profits,
CEREBROTEC shall receive an amount equal to the damages the court determines
CEREBROTEC has suffered as a result of the infringement less the amount of any
royalties that would have been due GENERAL on sales of PRODUCT lost by
CEREBROTEC as a result of the infringement had CEREBROTEC made such sales; and

                           (ii)     GENERAL shall receive an amount equal to the
royalties it would have received if such sales had been made by CEREBROTEC; and

                  (b)      As to awards other than those based on lost profits,
sixty (60) percent to the party initiating such proceedings and forth (40)
percent to the other party.

         7.4      For the purpose of the proceedings referred to in this Article
7, the GENERAL and CEREBROTEC shall permit the use of their names and shall
execute such documents and carry out such other acts as may be necessary. The
party initiating or carrying on such legal proceedings shall keep the other
party informed of the progress of such proceedings and said other party shall be
entitled to counsel in such proceedings but at its own expense, said expenses to
be off-set against any damages received by the party brining suit in accordance
with the foregoing paragraph 7.3.

         7.5      In the event that a declaratory judgment action or any other
action alleging invalidity, unenforceability, or non-infringement of any of the
PATENT RIGHTS or JOINT PATENT RIGHTS shall be brought against CEREBROTEC,
CEREBROTEC shall promptly notify GENERAL. CEREBROTEC shall have the sole right
to defend such action at its own expense, unless GENERAL, within thirty (30)
days after notification of such action, elects to intervene and take over the
sole defense of the action at its own expense.

                               8. INDEMNIFICATION

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
         8.1      (a)      CEREBROTEC shall indemnify, defend and hold harmless
GENERAL, CMCC and their trustees, officers, medical and professional staff,
employees, and agents and their respective successors, heirs and assigns (the
"Indemnitees"), against any liability, damage, loss or expense (including
reasonable attorney's fees and expenses of litigation) incurred by or imposed
upon the Indemnitees or any one of them in connection with any claims, suits,
actions, demands or judgments arising out of any theory of product liability
(including, but not limited to, actions in the form of tort, warranty, or strict
liability) concerning any product, process or service made, used or sold
pursuant to any right or license granted under this Agreement.

                  (b)      CEREBROTEC's indemnification under (a) above shall
not apply to any liability, damage, loss or expense to the extent that it is
directly attributable to the negligent activities, reckless misconduct or
intentional misconduct of the Indemnitees.

                  (c)      CEREBROTEC agrees, at its own expense to provide
attorneys reasonably acceptable to the GENERAL to defend against any actions
brought or filed against any party indemnified hereunder with respect to the
subject of indemnity contained herein, whether or not such actions are
rightfully brought.

                  (d)      This paragraph 8.1 shall survive expiration or
termination of this Agreement.

         8.2      (a)      Beginning at such time as any such product, process
or service is being commercially distributed or sold (other than for the purpose
of obtaining regulatory approvals) by CEREBROTEC or by a licensee, affiliate or
agent of CEREBROTEC, CEREBROTEC shall, at its sole cost and expense, procure and
maintain commercial general liability insurance in amounts not less than
$2,000,000 per incident and $2,000,000 annual aggregate and naming the
Indemnitees as additional insureds. Such commercial general liability insurance
shall provide (i) product liability coverage and (ii) broad form contractual
liability coverage for CEREBROTEC's indemnification under paragraph 8.1 of this
Agreement. If CEREBROTEC elects to self-insure all or part of the limits
described above (including deductibles or retentions which are in excess of
$250,000 annual aggregate) such self-insurance program must be acceptable to the
GENERAL, CMCC and the Risk Management Foundation. The minimum amounts of
insurance coverage required under this paragraph 8.2 shall not be construed to
create a limit of CEREBROTEC's liability with respect to its indemnification
under paragraph 8.1 of this Agreement.

                  (b)      CEREBROTEC shall provide GENERAL with written
evidence of such insurance upon request of GENERAL. CEREBROTEC shall provide
GENERAL with written notice at least fifteen (15) days prior to the
cancellation, non-renewal or material change in such insurance; if CEREBROTEC
does not obtain replacement insurance providing comparable coverage prior to the
expiration of such fifteen (15) day period, GENERAL shall have the right to
terminate this Agreement effective at the end of such fifteen (15) day period
without notice or any additional waiting periods.

                  (c)      CEREBROTEC shall maintain such commercial general
liability insurance beyond the expiration or termination of this Agreement
during (i) the period that any such product, process, or service is being
commercially distributed or sold (other than for the

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
purpose of obtaining regulatory approvals) by CEREBROTEC or by a licensee,
affiliate or agent of CEREBROTEC and (ii) a reasonable period after referred to
in (c)(i) above which in no even shall be less than fifteen (15) years.

                  (d)      This paragraph 8.2 shall survive expiration or
termination of this Agreement.

         8.3      OTHER THAN WARRANTIES SET FORTH HEREIN, GENERAL MAKES NO
WARRANTY, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED
WARRANTY OF MERCHANTABILITY OR ANY IMPLIED WARRANTY OF FITNESS FOR A PARTICULAR
PURPOSE WITH RESPECT TO ANY PATENT, TRADEMARK, SOFTWARE, TRADE SECRET, TANGIBLE
RESEARCH PROPERTY, INFORMATION OR DATA LICENSED OR OTHERWISE PROVIDED TO
CEREBROTEC HEREUNDER AND HEREBY DISCLAIMS THE SAME.

         8.4      GENERAL represents that, to the best of its knowledge as of
the EFFECTIVE DATE, there are no contractual obligations to other sponsors of
research at GENERAL or CMCC that would prohibit the granting of the rights and
licenses granted to CEREBROTEC herein.

                                 9. TERMINATION

         9.1      Unless otherwise terminated as provided for in this Agreement,
the license to PATENT RIGHTS and JOINT PATENT RIGHTS granted hereunder will
continue on a country by country basis:

                  (a)      for one (1) year after the date CEREBROTEC, its
AFFILIATES, or SUBLICENSEES shall last sell any PRODUCT in such country, it
being understood that GENERAL shall have the right to terminate such license
upon written notice in any country in the event that after the FIRST COMMERCIAL
SALE of PRODUCT in such country there is a continuous one (1) year period in
which no PRODUCT is sold in such country, provided such sale is not prevented by
force majeure, government regulation or intervention, or institution of a law
suit by any third party, or

                  (b)      until the last to expire of any PATENT RIGHT, the
claims of which but for this Agreement would be infringed by the manufacture,
use or sale of any PRODUCT in the applicable country, whichever shall first
occur.

         9.2      If either party shall fail to faithfully perform any of its
obligations under this Agreement except the due diligence milestones specified
in Article 3 herein, the nondefaulting party may give written notice of the
default to the defaulting party. Unless such default is corrected within thirty
(30) days after such notice, the notifying party may terminate this Agreement
and the license hereunder upon thirty (30) days' prior written notice, provided
that only one such thirty (30) day grace period shall be available in any twelve
(12) month period with respect to a default of any particular provision
hereunder. Thereafter notice of default of said provision shall constitute
termination.

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
         9.3      In the event that any license granted to CEREBROTEC under this
Agreement is terminated, any sublicense under such license granted prior to
termination of said license shall remain in full force and effect, provided
that:

                  (a)      the SUBLICENSEE is not then in breach of its
sublicense agreement;

                  (b)      the SUBLICENSEE agrees to be bound to GENERAL as the
licensor under the terms and conditions of its sublicense agreement, as modified
by the provisions of this paragraph 9.3;

                  (c)      the SUBLICENSEE, at GENERAL's written request,
assumes in a signed writing the same obligations to GENERAL as those assumed by
CEREBROTEC under Articles 8 and 10 hereof;

                  (d)      GENERAL shall have the right to receive the greater
of (a) any payments payable to CEREBROTEC under such sublicense agreement to the
extent they are reasonably and equitably attributable to such SUBLICENSEE's
right under such sublicense to use and exploit PATENT RIGHTS and/or JOINT PATENT
RIGHTS and/or TECHNOLOGICAL INFORMATION or (b) the lowest royalty which is
within the "Competitive" range as hereinafter defined, at the time GENERAL's
license to CEREBROTEC is terminated. A royalty rate shall be regarded as
"Competitive" if it is within the range of royalty rates that GENERAL would
charge in an arms length transaction with a licensee which was not and had not
been a sponsor of research at GENERAL, taking into account the value of the
licensed technology at the time GENERAL's license to CEREBROTEC is terminated;

                  (e)      the SUBLICENSEE agrees to be bound by the due
diligence obligations of CEREBROTEC pursuant to paragraph 3.1 hereof (whether
set by the parties or by Alternate Dispute Resolution pursuant to Section 10.9)
in the field and territory of the sublicense;

                  (f)      GENERAL has the right to terminate such sublicense
upon fifteen (15) days' prior written notice to CEREBROTEC and such SUBLICENSEE
in the event of any material breach of the obligation to make the payments
described in clause (iv) of this paragraph 9.3, unless such breach is cured
prior to the expiration of such fifteen (15) day period, and shall further have
the right to terminate such sublicense in the event of SUBLICENSEE's failure to
meet its due diligence obligations pursuant to clause (v) hereof;

                  (g)      GENERAL shall not assume, and shall not be
responsible to such SUBLICENSEE for, any representations, warranties or
obligations of CEREBROTEC to such SUBLICENSEE, other than to permit such
SUBLICENSEE to exercise any rights to PATENT RIGHTS and JOINT PATENT RIGHTS and
TECHNOLOGICAL INFORMATION that are granted under such sublicense agreement
consistent with the terms of this AGREEMENT.

         9.4 Upon termination of any license granted hereunder CEREBROTEC shall
pay GENERAL all royalties due or accrued on (i) the sale of PRODUCT up to and
including the date of termination and (ii) for twelve (12) months following the
date of termination, the sale of PRODUCT manufactured prior to the termination
date.

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
                               10. MISCELLANEOUS

         10.1     This Agreement constitutes the entire understanding between
the parties with respect to the subject matter hereof.

         10.2     In order to facilitate implementation of this Agreement,
GENERAL and CEREBROTEC are designating the following individuals to act on their
behalf with respect to this Agreement for the matter indicated below:

                  (a)      with respect to all royalty payments, any
correspondence pertaining to any PATENT RIGHT, or any notice of the use of
GENERAL's name, for GENERAL, the Director, Corporate Sponsored Research and
Licensing, and for CEREBROTEC, Seth P. Finklestein, M.D., President, Cerebrotec,
Inc., 308A Hunnewell St., Needham, MA 02494; provided that correspondence
relating to the billing of patent costs shall be copied to, for GENERAL, the
Business Manager, Corporate Sponsored Research and Licensing.

                  (b)      any amendment of or waiver under this Agreement, any
written notice including progress reports or other communication pertaining to
the Agreement: for GENERAL, the Director, Corporate Sponsored Research and
Licensing; and for CEREBROTEC, Seth P. Finklestein, M.D., President, Cerebrotec,
Inc., 308A Hunnewell St., Needham, MA 02494.

                  (c)      the above designations may be superseded from time to
time by alternative designations made by: for GENERAL, the Vice President for
Corporate Sponsored Research and Licensing and for CEREBROTEC, Seth P.
Finklestein, M.D., President, Cerebrotec, Inc., 308A Hunnewell St., Needham, MA
02494.

         10.3     This Agreement may be amended and any of its terms or
conditions may be waived only by a written instrument executed by the parties
or, in the case of a waiver, by the party waiving compliance. The failure of
either party at any time or times to require performance of any provision hereof
shall in no manner affect its rights at a later time to enforce the same. No
waiver by either party of any condition shall be deemed as a further or
continuing waiver of such condition or term or of any other condition or term.

         10.4     This Agreement shall be binding upon and inure to the benefit
of and be enforceable by the parties hereto and their respective successors and
permitted assigns.

         10.5     Any delays in or failures of performance by either party under
this Agreement shall not be considered a breach of this Agreement if and to the
extent caused by occurrences beyond the reasonable control of the party
affected, including but not limited to: Acts of God; acts, regulations or laws
of any government; strikes or their concerted acts of worker; fires; floods,
explosions; riots; wars; rebellion; and sabotage. Any time for performance
hereunder shall be extended by the actual time of delay caused by such
occurrence.

         10.6     Neither party shall use the name of the other party or CMCC or
of any staff member, officer, employee or student of the other party or CMCC or
any adaptation thereof in any advertising, promotional, or sales literature,
publicity or in any document employed to obtain

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
funds or financing without the prior written approval of the party or individual
whose name is to be used. For GENERAL, such approval shall be obtained from the
Director of Public Affairs.

         10.7     This Agreement shall be governed by and construed and
interpreted in accordance with the laws of the Commonwealth of Massachusetts.

         10.8     This Agreement shall not be assignable by GENERAL without
CEREBROTEC's written consent except for the right to receive royalties or other
payments payable herein. CEREBROTEC may at its own discretion and without
approval by GENERAL transfer its interest or any part thereof under this
Agreement to a wholly-owned subsidiary or, in the event of the merger,
consolidation or sale of substantially all of CEREBROTEC's assets or that
portion of CEREBROTEC's business to which this Agreement relates, to the
purchaser or assignee of said assets or to the surviving entity in any merger,
consolidation or acquisition. In the event of any such transfer, the transferee
shall assume and be bound by the provisions of this Agreement. Otherwise this
Agreement shall be assignable by CEREBROTEC only with the consent in writing of
GENERAL.

         10.9     For any and all claims, disputes, or controversies arising
under, out of, or in connection with this Agreement, except issues relating to
the validity, construction or effect of any PATENT RIGHT, which the parties
shall be unable to resolve within sixty (60) days, the party raising such
dispute shall promptly advise the other party of such claim, dispute, or
controversy in a writing which describes in reasonable detail the nature of such
dispute. By not later than five (5) business days after the recipient has
received such notice of dispute, each party shall have selected for itself a
representative who shall have the authority to bind such party and shall
additionally have advised the other party in writing of the name and title of
such representative. By not later than ten (10) business days after the date of
such notice of dispute, such representatives shall agree upon a third party
which is in the business of providing Alternative Dispute Resolution (ADR)
services (hereinafter, "ADR Provider") and shall schedule a date with such ADR
Provider to engage in ADR. Thereafter, the representatives of the parties shall
engage in good faith in an ADR process under the auspices of the selected ADR
Provider. If within the aforesaid thirty (30) business days after the date of
the notice of dispute the representatives of the parties have not been able to
agree upon an ADR Provider and schedule a date to engage in ADR, or if they have
not been able to resolve the dispute within thirty (30) business days after the
termination of ADR, the parties shall have the right to pursue any other
remedies legally available to resolve such dispute in either the Courts of the
Commonwealth of Massachusetts or in the United States District Court for the
District of Massachusetts, to whose jurisdiction for such purposes GENERAL and
CEREBROTEC hereby irrevocably consents and submits. Notwithstanding the
foregoing, nothing in this Paragraph 10.9 shall be construed to waiver any
rights or timely performance of any obligations existing under this Agreement.

         10.10    If any provision(s) of this Agreement are or become invalid,
are ruled illegal by any court of competent jurisdiction or are deemed
unenforceable under then current applicable law from time to time in effect
during the term hereof, it is the intention of the parties that the remainder of
this agreement shall not be effected thereby. It is further the intention of the
parties that in lieu of each such provision which is invalid, illegal or
unenforceable, there are substituted or added as part of this Agreement a
provision which shall be as similar as possible in economic

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
and business objectives as intended by the parties to such invalid, illegal or
enforceable provision, but shall be valid, legal and enforceable.

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
         THE PARTIES have duly executed this Agreement as of the date first
shown above written.

<TABLE>
<CAPTION>
CEREBROTEC, INC.                                           THE GENERAL HOSPITAL CORPORATION
<S>                                                        <C>
BY: Signature on File                                      BY: /s/ David Glass, Ph.D.

TITLE:  President                                          TITLE:  Assoc. Dir., Office. of Corp Sponsored
                                                           Research and Licensing

DATE:  2/5/01                                              DATE:  2/5/01
</TABLE>

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
                                   APPENDIX A
                                 PATENT RIGHTS

U.S. and foreign patent applications corresponding to the following inventions
and U.S. patent applications:

                                       [*]

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00033-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00033-of-00352.parquet"}]]